THE FOUNDATION FOR AIDS RESEARCH: Form 990, tax year 2012

View the entire original 990 at ProPublica ↗

Organization: THE FOUNDATION FOR AIDS RESEARCH (EIN 13-3163817)
Tax period: 2012-10-01 to 2013-09-30
Filed: 2014-06-18
IRS object ID: 201401699349300815
Schema version: 2012v2.3
Source: Download XML · Original 990 at ProPublica

Every field in the e-filed return. Faint text is the IRS element name, for citing.

Return header
Form 990
Schedule A
Schedule B
Schedule C
Schedule D
Schedule F
Schedule G
Schedule I
Schedule J
Schedule M
Schedule O

Return header ReturnHeader

Field	Value	IRS element (for citing)
Timestamp	2014-06-18T13:17:50-05:00	Timestamp
Tax Period End Date	2013-09-30	TaxPeriodEndDate

Preparer Firm PreparerFirm

Preparer Firm Business Name PreparerFirmBusinessName

Field	Value	IRS element (for citing)
Business Name Line1	GRANT THORNTON LLP	BusinessNameLine1

Preparer Firm US Address PreparerFirmUSAddress

Field	Value	IRS element (for citing)
Address Line1	666 THIRD AVENUE	AddressLine1
City	NEW YORK	City
State	NY	State
ZIP Code	100174057	ZIPCode

Field	Value	IRS element (for citing)
Return Type	990	ReturnType
Tax Period Begin Date	2012-10-01	TaxPeriodBeginDate

Filer Filer

Field	Value	IRS element (for citing)
EIN	133163817	EIN

Name Name

Field	Value	IRS element (for citing)
Business Name Line1	THE FOUNDATION FOR AIDS RESEARCH	BusinessNameLine1

Field	Value	IRS element (for citing)
In Care Of Name	% BRADLEY JENSEN	InCareOfName
Name Control	FOUN	NameControl
Phone	2128061600	Phone

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	120 wall street 13TH FLOOR	AddressLine1
Address Line2	Suite	AddressLine2
City	NEW YORK	City
State	NY	State
ZIP Code	100053908	ZIPCode

Officer Officer

Field	Value	IRS element (for citing)
Name	Please update	Name
Title	please update	Title
Phone	2125990100	Phone
Date Signed	2014-06-18	DateSigned
Authorize Third Party	true	AuthorizeThirdParty

Preparer Preparer

Field	Value	IRS element (for citing)
Phone	2125990100	Phone

Field	Value	IRS element (for citing)
Tax Year	2012	TaxYear
Build TS	2015-11-30 17:44:51Z	BuildTS

Form 990 IRS990

Doing Business As DoingBusinessAs

Field	Value	IRS element (for citing)
Business Name Line1	AMFAR	BusinessNameLine1

Field	Value	IRS element (for citing)
Name Of Principal Officer Person	KEVIN FROST	NameOfPrincipalOfficerPerson

Address Principal Officer US AddressPrincipalOfficerUS

Field	Value	IRS element (for citing)
Address Line1	120 WALL STREET 13TH FLOOR	AddressLine1
City	new york	City
State	NY	State
ZIP Code	10005	ZIPCode

Field	Value	IRS element (for citing)
Gross Receipts	50139259	GrossReceipts
Group Return For Affiliates	false	GroupReturnForAffiliates
Organization501c3	X	Organization501c3
Web Site	WWW.AMFAR.ORG	WebSite
Type Of Organization Corporation	X	TypeOfOrganizationCorporation
Year Formation	1983	YearFormation
State Legal Domicile	NY	StateLegalDomicile
Activity Or Mission Description	amfar is dedicated to ending the global aids epidemic through innovative research.	ActivityOrMissionDescription
Nbr Voting Members Governing Body	20	NbrVotingMembersGoverningBody
Nbr Independent Voting Members	20	NbrIndependentVotingMembers
Total Nbr Employees	91	TotalNbrEmployees
Total Nbr Volunteers	168	TotalNbrVolunteers
Total Gross UBI	0	TotalGrossUBI
Contributions Grants Prior Year	33247849	ContributionsGrantsPriorYear
Contributions Grants Current Year	38582579	ContributionsGrantsCurrentYear
Program Service Revenue Prior Year	0	ProgramServiceRevenuePriorYear
Program Service Revenue CY	0	ProgramServiceRevenueCY
Investment Income Prior Year	1178972	InvestmentIncomePriorYear
Investment Income Current Year	980398	InvestmentIncomeCurrentYear
Other Revenue Prior Year	-7234513	OtherRevenuePriorYear
Other Revenue Current Year	-9648345	OtherRevenueCurrentYear
Total Revenue Prior Year	27192308	TotalRevenuePriorYear
Total Revenue Current Year	29914632	TotalRevenueCurrentYear
Grants And Similar Amnts Prior Year	8086344	GrantsAndSimilarAmntsPriorYear
Grants And Similar Amnts CY	7997283	GrantsAndSimilarAmntsCY
Benefits Paid To Members Prior Year	0	BenefitsPaidToMembersPriorYear
Benefits Paid To Members CY	0	BenefitsPaidToMembersCY
Salaries Etc Prior Year	8864151	SalariesEtcPriorYear
Salaries Etc Current Year	9333804	SalariesEtcCurrentYear
Total Prof Fundrsng Exp Prior Year	491117	TotalProfFundrsngExpPriorYear
Total Prof Fundrsng Exp CY	470337	TotalProfFundrsngExpCY
Total Fundrsng Exp Current Year	4996086	TotalFundrsngExpCurrentYear
Other Expense Prior Year	11261191	OtherExpensePriorYear
Other Expenses Current Year	11457241	OtherExpensesCurrentYear
Total Expenses Prior Year	28702803	TotalExpensesPriorYear
Total Expenses Current Year	29258665	TotalExpensesCurrentYear
Revenues Less Expenses Prior Year	-1510495	RevenuesLessExpensesPriorYear
Revenues Less Expenses CY	655967	RevenuesLessExpensesCY
Total Assets BOY	40388195	TotalAssetsBOY
Total Assets EOY	50024337	TotalAssetsEOY
Total Liabilities BOY	9636091	TotalLiabilitiesBOY
Total Liabilities EOY	18892314	TotalLiabilitiesEOY
Net Assets Or Fund Balances BOY	30752104	NetAssetsOrFundBalancesBOY
Net Assets Or Fund Balances EOY	31132023	NetAssetsOrFundBalancesEOY
Info In Schedule O Part III	X	InfoInScheduleOPartIII
Mission Description	THE FOUNDATION FOR AIDS RESEARCH IS AN INTERNATIONAL NOT-FOR-PROFIT ORGANIZATION INCORPORATED IN NEW YORK IN 1989. AMFAR WAS FORMED THROUGH THE UNIFICATION IN 1985 OF TWO NOT-FOR-PROFIT ORGANIZATIONS, THE AIDS MEDICAL FOUNDATION ("AMF"), INCORPORATED IN NEW YORK IN APRIL 1983, AND THE NATIONAL AIDS RESEARCH FOUNDATION, INCORPORATED IN CALIFORNIA IN AUGUST 1985. FIRST BASED IN CALIFORNIA, AMFAR TRANSFERRED ITS LEGAL DOMICILE TO NEW YORK IN 1989, USING THE INITIAL INCORPORATION DOCUMENTS OF AMF, MAKING IT AMF'S LEGAL SUCCESSOR. AMFAR HAS OFFICES IN NEW YORK, NY, WASHINGTON, D.C., AND BANGKOK, THAILAND. ON MARCH 7, 2005, THE BOARD OF TRUSTEES OF THE AMERICAN FOUNDATION FOR AIDS RESEARCH APPROVED A CHANGE IN LEGAL NAME TO "THE FOUNDATION FOR AIDS RESEARCH." ON OCTOBER 18, 2005, THE NEW YORK STATE DEPARTMENT OF STATE APPROVED THIS CHANGE. IN ADDITION, THE FOUNDATION HAS SECURED APPROVAL FOR DOING BUSINESS AS (DBA) THE FOLLOWING: - AMERICAN FOUNDATION FOR AIDS RESEARCH - AMFAR - AIDS RESEARC	MissionDescription
Significant New Program Services	false	SignificantNewProgramServices
Significant Change	false	SignificantChange
Expense	8102469	Expense
Grants	4075650	Grants
Revenue	0	Revenue
Description	RESEARCH: amfAR supports research projects that explore novel approaches to scientifically sound but untested hypotheses in all areas of research on HIV/AIDS, funding goal-oriented studies that often lack the preliminary data required for support from traditional grant-makers. The Foundation plays a vital role in HIV/AIDS research, identifying critical gaps in knowledge and providing essential seed money that enables grantees and fellows to test the merits of new concepts or technologies that subsequently can be validated through large-scale studies, such as those funded by the National Institutes of Health. For further details, see Schedule o.	Description

Activity2 Activity2

Field	Value	IRS element (for citing)
Expense	6010188	Expense
Grants	2581709	Grants
Revenue	0	Revenue
Description	TREAT ASIA: amfAR's TREAT Asia program (Therapeutics Research, Education, and AIDS Training in Asia) involves a network of hospitals, clinics, and research institutions working with civil society to ensure the safe and effective delivery of HIV/AIDS treatments across Asia and the Pacific. The TREAT Asia Network encompasses 22 adult and 20 pediatric sites throughout the region, which collaborate on a variety of projects. For further details, see Schedule o.	Description

Activity3 Activity3

Field	Value	IRS element (for citing)
Expense	3426418	Expense
Grants	0	Grants
Revenue	0	Revenue
Description	EDUCATION AND INFORMATION: amfAR seeks to translate and disseminate information on important AIDS-related research, treatment, prevention, and policy issues for diverse audiences and to stimulate broad awareness of the need for better treatment and prevention methods. amfAR also publishes a wide range of educational materials, maintains an informative website, and engages respected public figures, HIV/AIDS scientists, and policy makers in communicating the need for continued research on HIV/AIDS. For further details, see Schedule O.	Description

Activity Other ActivityOther (2 entries)

ExpenseExpense	GrantsGrants	RevenueRevenue	DescriptionDescription
2363749	1132282	0	GMT Initiative
2039872	207642	0	public policy

Field	Value	IRS element (for citing)
Total Of Other Program Service Exp	4403621	TotalOfOtherProgramServiceExp
Total Of Other Program Service Grnt	1339924	TotalOfOtherProgramServiceGrnt
Total Of Other Program Service Rev	0	TotalOfOtherProgramServiceRev
Total Program Service Expense	21942696	TotalProgramServiceExpense
Described In501 C3	true	DescribedIn501C3
Schedule B Required	true	ScheduleBRequired
Political Activities	false	PoliticalActivities
Lobbying Activities	true	LobbyingActivities
Subject To Proxy Tax	false	SubjectToProxyTax
Donor Advised Funds	false	DonorAdvisedFunds
Conservation Easements	false	ConservationEasements
Collections Of Art	true	CollectionsOfArt
Credit Counseling	false	CreditCounseling
Term Or Permanent Endowments	true	TermOrPermanentEndowments
Report Land Bldg Equip	true	ReportLandBldgEquip
Report Invest Oth Securities	true	ReportInvestOthSecurities
Report Prog Rel Invest	false	ReportProgRelInvest
Report Other Assets	false	ReportOtherAssets
Report Other Liabilities	true	ReportOtherLiabilities
Report Fin48 Footnote	true	ReportFin48Footnote
Independent Audit Financial Stmt	true	IndependentAuditFinancialStmt
Consolidated Audit Financial Stmt	false	ConsolidatedAuditFinancialStmt
School	false	School
Foreign Office	true	ForeignOffice
Foreign Activities	true	ForeignActivities
More Than5000 K To Organizations	true	MoreThan5000KToOrganizations
More Than5000 K To Individuals	false	MoreThan5000KToIndividuals
Professional Fundraising	true	ProfessionalFundraising
Fundraising Activities	true	FundraisingActivities
Gaming	false	Gaming
Hospital	false	Hospital
Grants To Organizations	true	GrantsToOrganizations
Grants To Individuals	false	GrantsToIndividuals
Schedule J Required	true	ScheduleJRequired
Tax Exempt Bonds	false	TaxExemptBonds
Excess Benefit Transaction	false	ExcessBenefitTransaction
Prior Excess Benefit Transaction	false	PriorExcessBenefitTransaction
Loan To Officer Or DQP	false	LoanToOfficerOrDQP
Grant To Related Person	false	GrantToRelatedPerson
Bsnss Rltnshp With Organization	false	BsnssRltnshpWithOrganization
Bsnss Rltnshp Thru Family Member	false	BsnssRltnshpThruFamilyMember
Officer Entity With Bsnss Rltnshp	false	OfficerEntityWithBsnssRltnshp
Deductible Non Cash Contributions	true	DeductibleNonCashContributions
Deductible Contributions Of Art	false	DeductibleContributionsOfArt
Terminated	false	Terminated
Partial Liquidation	false	PartialLiquidation
Disregarded Entity	false	DisregardedEntity
Related Entity	false	RelatedEntity
Related Org Controlled Entity	false	RelatedOrgControlledEntity
Transfers To Exempt Non Chrtbl Org	false	TransfersToExemptNonChrtblOrg
Activities Conducted Partnership	false	ActivitiesConductedPartnership
Schedule O Required	true	ScheduleORequired
Number Forms Transmitted With1096	113	NumberFormsTransmittedWith1096
Number W2 G Included	0	NumberW2GIncluded
Compliance With Backup Witholding	true	ComplianceWithBackupWitholding
Number Of Employees	91	NumberOfEmployees
Employment Tax Returns Filed	true	EmploymentTaxReturnsFiled
Unrelated Business Income	false	UnrelatedBusinessIncome
Foreign Financial Account	true	ForeignFinancialAccount
Name Of Foreign Country	TH	NameOfForeignCountry
Prohibited Tax Shelter Trans	false	ProhibitedTaxShelterTrans
Taxable Party Notification	false	TaxablePartyNotification
Non Deductible Contributions	false	NonDeductibleContributions
Quid Pro Quo Contributions	true	QuidProQuoContributions
Quid Pro Quo Disclosure	true	QuidProQuoDisclosure
Form8282 Property Disposed Of	false	Form8282PropertyDisposedOf
Funds To Pay Premiums	false	FundsToPayPremiums
Premiums Paid	false	PremiumsPaid
Indoor Tanning Services	false	IndoorTanningServices
Info In Schedule O Part VI	X	InfoInScheduleOPartVI
Nbr Voting Governing Body Members	20	NbrVotingGoverningBodyMembers
Number Independent Voting Members	20	NumberIndependentVotingMembers
Family Or Business Relationship	false	FamilyOrBusinessRelationship
Delegation Of Management Duties	false	DelegationOfManagementDuties
Changes To Organizing Docs	false	ChangesToOrganizingDocs
Material Diversion Or Misuse	false	MaterialDiversionOrMisuse
Members Or Stockholders	false	MembersOrStockholders
Election Of Board Members	false	ElectionOfBoardMembers
Decisions Subject To Approval	false	DecisionsSubjectToApproval
Minutes Of Governing Body	true	MinutesOfGoverningBody
Minutes Of Committees	true	MinutesOfCommittees
Officer Mailing Address	false	OfficerMailingAddress
Local Chapters	false	LocalChapters
Form990 Provided To Governing Body	true	Form990ProvidedToGoverningBody
Conflict Of Interest Policy	true	ConflictOfInterestPolicy
Annual Disclosure Covered Persons	true	AnnualDisclosureCoveredPersons
Regular Monitoring Enforcement	true	RegularMonitoringEnforcement
Whistleblower Policy	true	WhistleblowerPolicy
Document Retention Policy	true	DocumentRetentionPolicy
Compensation Process CEO	true	CompensationProcessCEO
Compensation Process Other	true	CompensationProcessOther
Investment In Joint Venture	false	InvestmentInJointVenture
States Where Copy Of Return Is Filed	AL	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	AK	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	AZ	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	AR	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	CA	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	CT	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	FL	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	GA	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	HI	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	IL	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	KS	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	KY	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	ME	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	MD	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	MA	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	MI	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	MN	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	MS	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	NH	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	NJ	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	NM	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	NY	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	NC	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	OH	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	OK	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	OR	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	PA	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	RI	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	SC	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	TN	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	UT	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	VA	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	WV	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	WI	StatesWhereCopyOfReturnIsFiled
Own Website	X	OwnWebsite
Upon Request	X	UponRequest

The Books Are In Care Of TheBooksAreInCareOf

Field	Value	IRS element (for citing)
Name Person	BRADLEY JENSEN	NamePerson
Telephone Number	2128061703	TelephoneNumber

Address US AddressUS

Field	Value	IRS element (for citing)
Address Line1	120 WALL STREET 13TH FLOOR	AddressLine1
City	new york	City
State	NY	State
ZIP Code	100053908	ZIPCode

Form990 Part VII Section A Form990PartVIISectionA (41 entries)

TitleTitle	Average Hours Per WeekAverageHoursPerWeek	Individual Trustee Or DirectorIndividualTrusteeOrDirector	OfficerOfficer	Reportable Comp From OrganizationReportableCompFromOrganization	Reportable Comp From Related OrgsReportableCompFromRelatedOrgs	Other CompensationOtherCompensation	Key EmployeeKeyEmployee	Highest Compensated EmployeeHighestCompensatedEmployee
Mathilde Krim PhD
Founding Chairman	1.0	X	X
Kenneth Cole
Chairman of the Board	1.0	X	X
Patricia J Matson
Vice Chairman	1.0	X	X
John C Simons
Vice Chairman	1.0	X	X
Wallace Sheft CPA
Treasurer	1.0	X	X
Mervyn F Silverman MDMPH
Secretary	1.0	X	X
Arlen H Andelson
Trustee	1.0	X
Harry Belafonte
Trustee (NON-voting)	1.0	X
David Bohnett
Trustee	1.0	X
Zev Braun
Trustee (non-voting)	1.0	X
Jonathan S Canno
Trustee	1.0	X
Donald Capoccia
Trustee	1.0	X
R Martin Chavez PhD
Trustee	1.0	X
Jane B Eisner
Trustee (NON-voting)	1.0	X
T Ryan Greenawalt
Trustee	1.0	X
Regan Hofmann
Trustee	1.0	X
Michael J Klingensmith
Trustee	1.0	X
Michele V McNeill PharmD
Trustee (NON-Voting)	1.0	X
Edward Milstein
Trustee	1.0	X
Cindy Rachofsky
Trustee	1.0	X
Vincent A Roberti
Trustee	1.0	X
Bill Roedy
Trustee	1.0	X
Alan D Schwartz
Trustee (NON-VOTING)	1.0	X
Diana L Taylor
Trustee (NON-VOTING)	1.0	X
Kevin Wendle
Trustee (NON-VOTING)	1.0	X
Kevin McClatchy
Trustee	1.0	X
Raymond F Schinazi PhD
Trustee	1.0	X
Kevin Frost
Chief Executive Officer	40.0		X	385700	0	98183
Bradley Jensen
ASST Treasurer, CFO	40.0		X	217845	0	46789
John F Logan JD PhD
ASST Secretary, VP & GC	40.0		X	203482	0	24532
Rowena Johnston
ASST Secretary, VP OF RESEARCH	40.0		X	166901	0	21937
Edward Donnelly
ASST Treasurer, ControlleR	40.0		X	133796	0	18839
Gregory L Boroff
Vice President of Development	40.0			228217	0	26419	X
Christopher Collins
Vice President, Public Policy	40.0			192518	0	32356	X
Annette Sohn
Vice President, TREAT Asia	40.0			200613	0	19635	X
AnnMarie Shannahan
Vice President, Public Info	40.0			194344	0	23872	X
Eric Muscatell
Director, Philanthropy	40.0			157089	0	21477		X
Andrew McInnes
Director, Publications	40.0			134850	0	41195		X
Anthony Ancona
Vice President, Human Resource	40.0			155133	0	14211		X
Susan Doster
Chief Technology Officer	40.0			132775	0	19478		X
Bennah Serfaty
Senior Dir. of Communications	40.0			120255	0	39311		X

Field	Value	IRS element (for citing)
Total Reportable Comp From Org	2623518	TotalReportableCompFromOrg
Total Reportable Comp Frm Rltd Orgs	0	TotalReportableCompFrmRltdOrgs
Total Other Compensation	448234	TotalOtherCompensation
Number Individuals GT100 K	19	NumberIndividualsGT100K
Formers Listed	false	FormersListed
Total Comp GT150 K	true	TotalCompGT150K
Compensation From Other Sources	false	CompensationFromOtherSources

Contractor Compensation ContractorCompensation (5 entries)

Address Line1AddressOfContractor/AddressUS/AddressLine1	CityAddressOfContractor/AddressUS/City	StateAddressOfContractor/AddressUS/State	ZIP CodeAddressOfContractor/AddressUS/ZIPCode	Description Of ServicesDescriptionOfServices	CompensationCompensation
JOSH WOODS PRODUCTION
39 WEST 14TH STREET SUITE 504	NEW YORK	NY	10011	events production	448921
AAB PRODUCTIONS
64 ALLEN ROAD 5TH FLOOR	NEW YORK	NY	10002	EVENTS PRODUCTION	252500
GRANT THORNTON LLP
1901 W MEYERS ROAD SUITE 455	OAKBROOK TERRACE	IL	60181	ACCOUNTING & AUDIT	151260
THE MORRIS KING COMPANY LLC
101 FIFTH AVENUE 8TH FLOOR	NEW YORK	NY	10003	PUBLIC RELATIONS	148000
GLOBAL HEALTH INSTITUTE LLC
5530 WISCONSIN AVENUE SUITE 1255	CHEVY CHASE	MD	20815	PROGRAM DEVELOPMENT	110368

Field	Value	IRS element (for citing)
Number Of Contractors GT100 K	6	NumberOfContractorsGT100K
Federated Campaigns	461323	FederatedCampaigns
Fundraising Events	26085758	FundraisingEvents
Government Grants	4641815	GovernmentGrants
All Other Contributions	7393683	AllOtherContributions
Noncash Contributions	104103	NoncashContributions
Total Contributions	38582579	TotalContributions
Total Program Service Revenue	0	TotalProgramServiceRevenue

Investment Income InvestmentIncome

Field	Value	IRS element (for citing)
Total Revenue Column	708016	TotalRevenueColumn
Exclusion	$708,016	ExclusionAmount

Income From Invest Bond Proceeds IncomeFromInvestBondProceeds

Field	Value	IRS element (for citing)
Total Revenue Column	0	TotalRevenueColumn

Royalties Revenue RoyaltiesRevenue

Field	Value	IRS element (for citing)
Total Revenue Column	47277	TotalRevenueColumn
Exclusion	$47,277	ExclusionAmount

Rental Income Or Loss RentalIncomeOrLoss

Field	Value	IRS element (for citing)
Real	0	Real
Personal	0	Personal

Net Rental Income Or Loss NetRentalIncomeOrLoss

Field	Value	IRS element (for citing)
Total Revenue Column	0	TotalRevenueColumn

Gross Amount Sales Assets GrossAmountSalesAssets

Field	Value	IRS element (for citing)
Securities	9227075	Securities

Less Cost Oth Basis Sales Expenses LessCostOthBasisSalesExpenses

Field	Value	IRS element (for citing)
Securities	8954693	Securities

Gain Or Loss GainOrLoss

Field	Value	IRS element (for citing)
Securities	272382	Securities

Net Gain Or Loss Investments NetGainOrLossInvestments

Field	Value	IRS element (for citing)
Total Revenue Column	272382	TotalRevenueColumn
Exclusion	$272,382	ExclusionAmount

Field	Value	IRS element (for citing)
Gross Income Fundraising Events	1357200	GrossIncomeFundraisingEvents
Cntrbtns Rprtd Fundraising Events	26085758	CntrbtnsRprtdFundraisingEvents
Fundraising Direct Expenses	11216365	FundraisingDirectExpenses

Net Income From Fundraising Events NetIncomeFromFundraisingEvents

Field	Value	IRS element (for citing)
Total Revenue Column	-9859165	TotalRevenueColumn
Exclusion	-$9,859,165	ExclusionAmount

Net Income From Gaming NetIncomeFromGaming

Field	Value	IRS element (for citing)
Total Revenue Column	0	TotalRevenueColumn

Field	Value	IRS element (for citing)
Gross Sales Of Inventory	103590	GrossSalesOfInventory
Cost Of Goods Sold	53569	CostOfGoodsSold

Net Income Or Loss NetIncomeOrLoss

Field	Value	IRS element (for citing)
Total Revenue Column	157159	TotalRevenueColumn
Exclusion	$157,159	ExclusionAmount

Other Revenue Misc OtherRevenueMisc (2 entries)

DescriptionDescription	Business CodeBusinessCode	Total Revenue ColumnTotalRevenueColumn	ExclusionExclusionAmount
LIST RENTALS	900099	5477	$5,477
MISCELLANEOUS INCOME	900099	907	$907

Field	Value	IRS element (for citing)
Total Other Revenue	6384	TotalOtherRevenue

Total Revenue TotalRevenue

Field	Value	IRS element (for citing)
Total Revenue Column	29914632	TotalRevenueColumn
Exclusion	-$8,667,947	ExclusionAmount

Field	Value	IRS element (for citing)
Info In Schedule O Part IX	X	InfoInScheduleOPartIX

Grants To Domestic Orgs GrantsToDomesticOrgs

Field	Value	IRS element (for citing)
Total	3633934	Total
Program Services	3633934	ProgramServices

Grants To Domestic Individuals GrantsToDomesticIndividuals

Field	Value	IRS element (for citing)
Total	0	Total

Foreign Grants ForeignGrants

Field	Value	IRS element (for citing)
Total	4363349	Total
Program Services	4363349	ProgramServices

Benefits To Members BenefitsToMembers

Field	Value	IRS element (for citing)
Total	0	Total

Comp Current Officers Directors CompCurrentOfficersDirectors

Field	Value	IRS element (for citing)
Total	2291708	Total
Program Services	1514295	ProgramServices
Management And General	441710	ManagementAndGeneral
Fundraising	335703	Fundraising

Comp Disqual Persons CompDisqualPersons

Field	Value	IRS element (for citing)
Total	0	Total

Other Salaries And Wages OtherSalariesAndWages

Field	Value	IRS element (for citing)
Total	5216798	Total
Program Services	3553662	ProgramServices
Management And General	392009	ManagementAndGeneral
Fundraising	1271127	Fundraising

Pension Plan Contributions PensionPlanContributions

Field	Value	IRS element (for citing)
Total	296141	Total
Program Services	199278	ProgramServices
Management And General	23426	ManagementAndGeneral
Fundraising	73437	Fundraising

Other Employee Benefits OtherEmployeeBenefits

Field	Value	IRS element (for citing)
Total	1048235	Total
Program Services	668360	ProgramServices
Management And General	133335	ManagementAndGeneral
Fundraising	246540	Fundraising

Payroll Taxes PayrollTaxes

Field	Value	IRS element (for citing)
Total	480922	Total
Program Services	309774	ProgramServices
Management And General	56428	ManagementAndGeneral
Fundraising	114720	Fundraising

Fees For Services Management FeesForServicesManagement

Field	Value	IRS element (for citing)
Total	0	Total

Fees For Services Legal FeesForServicesLegal

Field	Value	IRS element (for citing)
Total	185935	Total
Program Services	147812	ProgramServices
Management And General	19932	ManagementAndGeneral
Fundraising	18191	Fundraising

Fees For Services Accounting FeesForServicesAccounting

Field	Value	IRS element (for citing)
Total	167426	Total
Management And General	167426	ManagementAndGeneral

Fees For Services Lobbying FeesForServicesLobbying

Field	Value	IRS element (for citing)
Total	62807	Total
Program Services	62807	ProgramServices

Fees For Services Prof Fundraising FeesForServicesProfFundraising

Field	Value	IRS element (for citing)
Total	470337	Total
Fundraising	470337	Fundraising

Fees For Services Invst Mgmnt Fees FeesForServicesInvstMgmntFees

Field	Value	IRS element (for citing)
Total	164418	Total
Management And General	164418	ManagementAndGeneral

Fees For Services Other FeesForServicesOther

Field	Value	IRS element (for citing)
Total	1298183	Total
Program Services	924659	ProgramServices
Management And General	49164	ManagementAndGeneral
Fundraising	324360	Fundraising

Advertising Advertising

Field	Value	IRS element (for citing)
Total	476903	Total
Program Services	473959	ProgramServices
Management And General	1184	ManagementAndGeneral
Fundraising	1760	Fundraising

Office Expenses OfficeExpenses

Field	Value	IRS element (for citing)
Total	109631	Total
Program Services	55430	ProgramServices
Management And General	7621	ManagementAndGeneral
Fundraising	46580	Fundraising

Information Technology InformationTechnology

Field	Value	IRS element (for citing)
Total	174371	Total
Program Services	128295	ProgramServices
Management And General	23985	ManagementAndGeneral
Fundraising	22091	Fundraising

Royalties Royalties

Field	Value	IRS element (for citing)
Total	0	Total

Occupancy Occupancy

Field	Value	IRS element (for citing)
Total	1231775	Total
Program Services	869859	ProgramServices
Management And General	159658	ManagementAndGeneral
Fundraising	202258	Fundraising

Travel Travel

Field	Value	IRS element (for citing)
Total	836636	Total
Program Services	394275	ProgramServices
Management And General	881	ManagementAndGeneral
Fundraising	441480	Fundraising

Travel Entrtnmnt Public Officials TravelEntrtnmntPublicOfficials

Field	Value	IRS element (for citing)
Total	0	Total

Conferences Meetings ConferencesMeetings

Field	Value	IRS element (for citing)
Total	858596	Total
Program Services	746815	ProgramServices
Management And General	8077	ManagementAndGeneral
Fundraising	103704	Fundraising

Interest Interest

Field	Value	IRS element (for citing)
Total	8	Total
Management And General	8	ManagementAndGeneral

Payments To Affiliates PaymentsToAffiliates

Field	Value	IRS element (for citing)
Total	0	Total

Depreciation Depletion DepreciationDepletion

Field	Value	IRS element (for citing)
Total	415252	Total
Program Services	293370	ProgramServices
Management And General	53847	ManagementAndGeneral
Fundraising	68035	Fundraising

Insurance Insurance

Field	Value	IRS element (for citing)
Total	197026	Total
Program Services	139196	ProgramServices
Management And General	25549	ManagementAndGeneral
Fundraising	32281	Fundraising

Other Expenses OtherExpenses (4 entries)

DescriptionDescription	TotalTotal	Program ServicesProgramServices	Management And GeneralManagementAndGeneral	FundraisingFundraising
PROGRAM MATERIALS	1425070	1425070	0	0
POSTAGE & SHIPPING	761994	345771	5618	410605
PRINTING	745975	275663	745	469567
PROGRAM TECHNICAL SUPPORT	598873	598873	0	0

All Other Expenses AllOtherExpenses

Field	Value	IRS element (for citing)
Total	1746362	Total
Program Services	818190	ProgramServices
Management And General	584862	ManagementAndGeneral
Fundraising	343310	Fundraising

Total Functional Expenses TotalFunctionalExpenses

Field	Value	IRS element (for citing)
Total	29258665	Total
Program Services	21942696	ProgramServices
Management And General	2319883	ManagementAndGeneral
Fundraising	4996086	Fundraising

Field	Value	IRS element (for citing)
Joint Costs	X	JointCosts

Total Joint Costs TotalJointCosts

Field	Value	IRS element (for citing)
Total	999371	Total
Program Services	377734	ProgramServices
Fundraising	621637	Fundraising

Cash Non Interest Bearing CashNonInterestBearing

Field	Value	IRS element (for citing)
BOY	6129973	BOY
EOY	8001602	EOY

Savings And Temp Cash Investments SavingsAndTempCashInvestments

Field	Value	IRS element (for citing)
BOY	216445	BOY
EOY	539347	EOY

Pledges And Grants Receivable PledgesAndGrantsReceivable

Field	Value	IRS element (for citing)
BOY	203639	BOY
EOY	205706	EOY

Accounts Receivable AccountsReceivable

Field	Value	IRS element (for citing)
BOY	3725105	BOY
EOY	10267012	EOY

Receivables From Officers Etc ReceivablesFromOfficersEtc

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Receivables From Disqual Persons ReceivablesFromDisqualPersons

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Other Notes Loans Receivable Net OtherNotesLoansReceivableNet

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Inventories For Sale Or Use InventoriesForSaleOrUse

Field	Value	IRS element (for citing)
BOY	75665	BOY
EOY	133906	EOY

Prepaid Expenses Deferred Charges PrepaidExpensesDeferredCharges

Field	Value	IRS element (for citing)
BOY	705507	BOY
EOY	1401620	EOY

Field	Value	IRS element (for citing)
Land Buildings Equipment Basis	5156241	LandBuildingsEquipmentBasis
Land Bldg Equipment Accum Deprec	3180930	LandBldgEquipmentAccumDeprec

Land Buildings Equipment Basis Net LandBuildingsEquipmentBasisNet

Field	Value	IRS element (for citing)
BOY	1888607	BOY
EOY	1975311	EOY

Investments Pub Traded Securities InvestmentsPubTradedSecurities

Field	Value	IRS element (for citing)
BOY	23016384	BOY
EOY	23656458	EOY

Investments Other Securities InvestmentsOtherSecurities

Field	Value	IRS element (for citing)
BOY	4233643	BOY
EOY	3169232	EOY

Investments Program Related InvestmentsProgramRelated

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Intangible Assets IntangibleAssets

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Other Assets Total OtherAssetsTotal

Field	Value	IRS element (for citing)
BOY	193227	BOY
EOY	674143	EOY

Total Assets TotalAssets

Field	Value	IRS element (for citing)
BOY	40388195	BOY
EOY	50024337	EOY

Accounts Payable Accrued Expenses AccountsPayableAccruedExpenses

Field	Value	IRS element (for citing)
BOY	1732740	BOY
EOY	1688090	EOY

Grants Payable GrantsPayable

Field	Value	IRS element (for citing)
BOY	1713122	BOY
EOY	2200512	EOY

Deferred Revenue DeferredRevenue

Field	Value	IRS element (for citing)
BOY	5428345	BOY
EOY	13321993	EOY

Tax Exempt Bond Liabilities TaxExemptBondLiabilities

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Escrow Account Liability EscrowAccountLiability

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Loans From Officers Directors LoansFromOfficersDirectors

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Mort Notes Pybl Secured Invest Prop MortNotesPyblSecuredInvestProp

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Unsecured Notes Loans Payable UnsecuredNotesLoansPayable

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Other Liabilities OtherLiabilities

Field	Value	IRS element (for citing)
BOY	761884	BOY
EOY	1681719	EOY

Total Liabilities TotalLiabilities

Field	Value	IRS element (for citing)
BOY	9636091	BOY
EOY	18892314	EOY

Field	Value	IRS element (for citing)
Follow SFAS117	X	FollowSFAS117

Unrestricted Net Assets UnrestrictedNetAssets

Field	Value	IRS element (for citing)
BOY	21921458	BOY
EOY	23555115	EOY

Temporarily Restricted Net Assets TemporarilyRestrictedNetAssets

Field	Value	IRS element (for citing)
BOY	8493158	BOY
EOY	7236209	EOY

Permanently Restricted Net Assets PermanentlyRestrictedNetAssets

Field	Value	IRS element (for citing)
BOY	337488	BOY
EOY	340699	EOY

Total Net Assets Fund Balances TotalNetAssetsFundBalances

Field	Value	IRS element (for citing)
BOY	30752104	BOY
EOY	31132023	EOY

Total Liab Net Assets Fund Balances TotalLiabNetAssetsFundBalances

Field	Value	IRS element (for citing)
BOY	40388195	BOY
EOY	50024337	EOY

Field	Value	IRS element (for citing)
Info In Schedule O Part XI	X	InfoInScheduleOPartXI
Reconcilation Revenue Expenses	655967	ReconcilationRevenueExpenses
Reconciliation Unrealized Invest	-246161	ReconciliationUnrealizedInvest
Reconcilation Other Changes	-29887	ReconcilationOtherChanges
Method Of Accounting Accrual	X	MethodOfAccountingAccrual
Accountant Compile Or Review	false	AccountantCompileOrReview
FS Audited	true	FSAudited

FS Audited Basis FSAuditedBasis

Field	Value	IRS element (for citing)
Financial Statement Separate	X	FinancialStatementSeparate

Field	Value	IRS element (for citing)
Audit Committee	true	AuditCommittee
Federal Grant Audit Required	true	FederalGrantAuditRequired
Federal Grant Audit Performed	true	FederalGrantAuditPerformed

Schedule A IRS990ScheduleA

Field	Value	IRS element (for citing)
Publicly Supported Org170b1 Avi	X	PubliclySupportedOrg170b1Avi

Gifts Grants Contrib Received170 GiftsGrantsContribReceived170

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	20760601	CurrentTaxYearMinus4Years
Current Tax Year Minus3 Years	22553697	CurrentTaxYearMinus3Years
Current Tax Year Minus2 Years	22876129	CurrentTaxYearMinus2Years
Current Tax Year Minus1 Year	33247849	CurrentTaxYearMinus1Year
Current Tax Year	38582579	CurrentTaxYear
Total	138020855	Total

Tax Rev Levied For Org Benefit170 TaxRevLeviedForOrgBenefit170

Field	Value	IRS element (for citing)
Total	0	Total

Value Srvc Fclts Furnished By Govt ValueSrvcFcltsFurnishedByGovt

Field	Value	IRS element (for citing)
Total	0	Total

Total170 Total170

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	20760601	CurrentTaxYearMinus4Years
Current Tax Year Minus3 Years	22553697	CurrentTaxYearMinus3Years
Current Tax Year Minus2 Years	22876129	CurrentTaxYearMinus2Years
Current Tax Year Minus1 Year	33247849	CurrentTaxYearMinus1Year
Current Tax Year	38582579	CurrentTaxYear
Total	138020855	Total

Field	Value	IRS element (for citing)
Amounts Subst Contributors Total	5256686	AmountsSubstContributorsTotal
Public Support Total170	132764169	PublicSupportTotal170

Gross Investment Income170 GrossInvestmentIncome170

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	643473	CurrentTaxYearMinus4Years
Current Tax Year Minus3 Years	668573	CurrentTaxYearMinus3Years
Current Tax Year Minus2 Years	951963	CurrentTaxYearMinus2Years
Current Tax Year Minus1 Year	897974	CurrentTaxYearMinus1Year
Current Tax Year	755293	CurrentTaxYear
Total	3917276	Total

Net UBI NetUBI

Field	Value	IRS element (for citing)
Total	0	Total

Other Income170 OtherIncome170

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	155966	CurrentTaxYearMinus4Years
Current Tax Year Minus3 Years	2756152	CurrentTaxYearMinus3Years
Current Tax Year Minus2 Years	1735330	CurrentTaxYearMinus2Years
Current Tax Year Minus1 Year	1624966	CurrentTaxYearMinus1Year
Current Tax Year	1467174	CurrentTaxYear
Total	7739588	Total

Field	Value	IRS element (for citing)
Total Support	149677719	TotalSupport
Gross Receipts From Admissions Etc	0	GrossReceiptsFromAdmissionsEtc
Public Support Pertcentage170	0.88700	PublicSupportPertcentage170
Public Support Pertcent Prior Year	0.90865	PublicSupportPertcentPriorYear
Thirty Three Percnt Tests CY170	X	ThirtyThreePercntTestsCY170

Schedule B IRS990ScheduleB

Contributor Info ContributorInfo

Field	Value	IRS element (for citing)
Contributor Number	RESTRICTED	ContributorNumber

Contributor Name Business ContributorNameBusiness

Field	Value	IRS element (for citing)
Business Name Line1	RESTRICTED	BusinessNameLine1

Contributor Address US ContributorAddressUS

Field	Value	IRS element (for citing)
Address Line1	RESTRICTED	AddressLine1
Address Line2	RESTRICTED	AddressLine2
City	RESTRICTED	City
State	RESTRICTED	State
ZIP Code	RESTRICTED	ZIPCode

Field	Value	IRS element (for citing)
Aggregate Contributions	RESTRICTED	AggregateContributions

Schedule C IRS990ScheduleC

Field	Value	IRS element (for citing)
Total Grassroots Lobbying		TotalGrassrootsLobbying
Total Direct Lobbying		TotalDirectLobbying
Total Lobbying Expenditures		TotalLobbyingExpenditures
Other Exempt Purpose Expenditures		OtherExemptPurposeExpenditures
Total Exempt Purpose Expenditures		TotalExemptPurposeExpenditures
Lobbying Nontaxable		LobbyingNontaxableAmount
Grassroots Nontaxable		GrassrootsNontaxableAmount
Tot Lobbying Grassroot Minus Non Tx		TotLobbyingGrassrootMinusNonTx
Tot Lobby Expend Mns Lobbying Nontx		TotLobbyExpendMnsLobbyingNontx
Volunteers	false	Volunteers
Paid Staff Or Management	true	PaidStaffOrManagement
Media Advertisements	false	MediaAdvertisements
Mailings Members	false	MailingsMembers
Publications Or Broadcast	false	PublicationsOrBroadcast
Grants Other Organizations	false	GrantsOtherOrganizations
Direct Contact Legislators	false	DirectContactLegislators
Rallies Demonstrations	false	RalliesDemonstrations
Other Activities	true	OtherActivities
Other Activities	$187,171	OtherActivitiesAmount
Total Lobbying Expenditures IIB	187171	TotalLobbyingExpendituresIIB
Not Described In501c3	false	NotDescribedIn501c3
Form4720 Filed4912 Tax	false	Form4720Filed4912Tax

Form990 Schedule C Part IV Form990ScheduleCPartIV

Field	Value	IRS element (for citing)
Identifier	Lobbying Expenses	Identifier
Return Reference	Part II-B	ReturnReference
Explanation	The Foundation for AIDS Research developed an Action Agenda to End AIDS that identified critical decisions that need to be made to advance evidence based AIDS policies. We created a variety of issue briefs on topics such as the potential impact of various budget scenarios on global health services, and policy priorities to address the HIV epidemic among gay men in the US. These issue briefs were shared with Capitol Hill staff and members of the Administration. amfAR met regularly with staff to members of Congress and with Administration staff, and we provided input to the Administration on development of the PEPFAR Blueprint for an AIDS Free Generation. amfAR sponsored several briefings on Capitol Hill on AIDS policy and research issues. amfAR uses these briefings as an educational tool.	Explanation

Schedule D IRS990ScheduleD

Art Public Exhibition Amts ArtPublicExhibitionAmts

Field	Value	IRS element (for citing)
Assets In Part X	149840	AssetsInPartX

Field	Value	IRS element (for citing)
Held Works Of Art Amts		HeldWorksOfArtAmts

Collection Used For Other CollectionUsedForOther

Field	Value	IRS element (for citing)
Collection Used For Other Purposes	X	CollectionUsedForOtherPurposes
Description Of Other Purposes	Donated Items, Inventory etc.	DescriptionOfOtherPurposes

Field	Value	IRS element (for citing)
Solicited Assets For Sale	true	SolicitedAssetsForSale

Current Year CurrentYear

Field	Value	IRS element (for citing)
Beginning Of Year Balance	520804	BeginningOfYearBalance
Contributions	3211	Contributions
Investment Earnings Or Losses	20742	InvestmentEarningsOrLosses
Other Expenditures	100871	OtherExpenditures
End Of Year Balance	443886	EndOfYearBalance

Current Year Minus1 Year CurrentYearMinus1Year

Field	Value	IRS element (for citing)
Beginning Of Year Balance	464356	BeginningOfYearBalance
Contributions	4341	Contributions
Investment Earnings Or Losses	52107	InvestmentEarningsOrLosses
End Of Year Balance	520804	EndOfYearBalance

Current Year Minus2 Years CurrentYearMinus2Years

Field	Value	IRS element (for citing)
Beginning Of Year Balance	561083	BeginningOfYearBalance
Contributions	5978	Contributions
Investment Earnings Or Losses	-2705	InvestmentEarningsOrLosses
Other Expenditures	100000	OtherExpenditures
End Of Year Balance	464356	EndOfYearBalance

Current Year Minus3 Years CurrentYearMinus3Years

Field	Value	IRS element (for citing)
Beginning Of Year Balance	516826	BeginningOfYearBalance
Contributions	8258	Contributions
Investment Earnings Or Losses	35999	InvestmentEarningsOrLosses
End Of Year Balance	561083	EndOfYearBalance

Current Year Minus4 Years CurrentYearMinus4Years

Field	Value	IRS element (for citing)
Beginning Of Year Balance	470065	BeginningOfYearBalance
Contributions	9378	Contributions
Investment Earnings Or Losses	37383	InvestmentEarningsOrLosses
End Of Year Balance	516826	EndOfYearBalance

Field	Value	IRS element (for citing)
Permanent Endowment EOY Balance	0.76754	PermanentEndowmentEOYBalance
Term Endowment EOY Balance	0.23246	TermEndowmentEOYBalance
Endowments Held By Unrelated Orgs	false	EndowmentsHeldByUnrelatedOrgs
Endowments Held By Related Orgs	false	EndowmentsHeldByRelatedOrgs
Land		Land
Buildings		Buildings

Leasehold Improvements LeaseholdImprovements

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	2101499	OtherCostOrOtherBasis
Depreciation	648256	Depreciation
Book Value	1453243	BookValue

Equipment Equipment

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	305895	OtherCostOrOtherBasis
Depreciation	249847	Depreciation
Book Value	56048	BookValue

Other Land Buildings OtherLandBuildings

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	2748847	OtherCostOrOtherBasis
Depreciation	2282827	Depreciation
Book Value	466020	BookValue

Field	Value	IRS element (for citing)
Total Of Book Value Land Buildings	1975311	TotalOfBookValueLandBuildings
Financial Derivatives		FinancialDerivatives
Closely Held Equity Interests		CloselyHeldEquityInterests

Other Securities OtherSecurities

Field	Value	IRS element (for citing)
Description	BENEFICIAL INTEREST IN TRUST	Description
Book Value	3169232	BookValue
Method Of Valuation	F	MethodOfValuation

Field	Value	IRS element (for citing)
Total Of Book Value Securities	3169232	TotalOfBookValueSecurities
Federal Income Tax Liability	0	FederalIncomeTaxLiability

Other Liabilities OtherLiabilities (2 entries)

DescriptionDescription	AmountAmount
LONG TERM LEASE LIABILITY	$1,535,854
SECTION 457 RETIREMENT LIABILITIES	$145,865

Field	Value	IRS element (for citing)
Total Of Amounts	1681719	TotalOfAmounts
Footnote In Part XIII	X	FootnoteInPartXIII
Tot Revenue Etc Audited Fincl Stmt	29942921	TotRevenueEtcAuditedFinclStmt
Net Unrealized Gains Investments	-246161	NetUnrealizedGainsInvestments
Donated Srvc And Use Of Facilities	304337	DonatedSrvcAndUseOfFacilities
Other Revenues	-29887	OtherRevenues
Revenue Not Rptd F990	28289	RevenueNotRptdF990
Revenue Subtotal	29914632	RevenueSubtotal
Total Revenue Per Form990	29914632	TotalRevenuePerForm990
Tot Expenses Etc Audited Fincl Stmt	29563002	TotExpensesEtcAuditedFinclStmt
Donated Services Use Of Facilities	304337	DonatedServicesUseOfFacilities
Expenses Not Rptd F990	304337	ExpensesNotRptdF990
Expenses Subtotal	29258665	ExpensesSubtotal
Total Expenses Per Form990	29258665	TotalExpensesPerForm990

Form990 Schedule D Part XIII Form990ScheduleDPartXIII (4 entries)

IdentifierIdentifier	Return ReferenceReturnReference	ExplanationExplanation
Endowments	Part V, Line 4	AMFAR's endowment fund is intended to fund the various general research programs the organization sponsors.
FIN 48	Income taxes	Amfar follows guidance that clarifies the accounting for uncertainty in tax positions taken or expected to be taken in a tax return, including issues relating to financial statement recognition and guidance on measurement, classification, interest and penalties, and disclosure. As of September 30, 2013, amfar does not believe that there are any uncertain tax positions within its financial statements. Amfar has processes presently in place to ensure the maintenance of its tax-exempt status; to identify and report unrelated income; to determine its filing and tax obligations in jurisdictions for which it has nexus; and to identify and evaluate other matters that may be considered tax positions. The tax years ended 2010, 2011, 2012, and 2013 are still open to audit for both federal and state purposes.
Collections of Art, Histocial Treasures, or other similar assets	Part III, Line 4	AMFAR holds various items of jewelry, photographs and other items of artistic value that have been donated to the organization for sale at special events. The organization has maintained these items in inventory for a few years and is in the process of selling them.
RECONCILIATION OF REVENUE	PART XI, LINE 2D	CHANGE IN VALUE OF THIRD PARTY TRUST ($29,887)

Schedule F IRS990ScheduleF

Field	Value	IRS element (for citing)
Grant Records Maintained	true	GrantRecordsMaintained

Accts Actvs Out US Table AcctsActvsOutUSTable (13 entries)

RegionRegion	Type Of Activities ConductedTypeOfActivitiesConducted	Specific Services ProvidedSpecificServicesProvided	Total ExpendituresTotalExpenditures	Number Of OfficesNumberOfOffices	Number Of EmployeesNumberOfEmployees
Central America and the Caribbean	Grantmaking	N/A	177540
East Asia and the Pacific	Grantmaking	N/A	2604045	1	19
Europe (Including Iceland and Greenland)	Grantmaking	N/A	656607
Middle East and North Africa	Grantmaking	N/A	20000
North America	Grantmaking	N/A	150000
Russia and the Newly Independent States	Grantmaking	N/A	97179
South America	Grantmaking	N/A	249759
South Asia	Grantmaking	N/A	56965
Sub-Saharan Africa	Grantmaking	N/A	351253
East Asia and the Pacific	Program Services	therapeutics research	2889590
Europe (Including Iceland and Greenland)	Fundraising		5474457
North America	Fundraising		435325
South America	Fundraising		900829

Field	Value	IRS element (for citing)
Subtotal Number Of Offices	1	SubtotalNumberOfOffices
Subtotal Number Of Employees	19	SubtotalNumberOfEmployees
Total Number Of Offices	1	TotalNumberOfOffices
Total Number Of Employees	19	TotalNumberOfEmployees
Subtotal Amount Spent	14063549	SubtotalAmountSpent
Total Amount Spent	14063549	TotalAmountSpent

Grants To Orgs Outside US GrantsToOrgsOutsideUS (159 entries)

RegionRegion	Purpose Of GrantPurposeOfGrant	Amount Of Cash GrantAmountOfCashGrant	Manner Of Cash DisbursementMannerOfCashDisbursement
Central America and the Caribbean	GMT INITIATIVE	12000	wire transfe
Central America and the Caribbean	GMT INITIATIVE	17500	wire transfe
Central America and the Caribbean	GMT INITIATIVE	17500	wire transfe
Central America and the Caribbean	GMT INITIATIVE	17500	wire transfe
Central America and the Caribbean	GMT INITIATIVE	14700	wire transfe
Central America and the Caribbean	GMT INITIATIVE	19250	wire transfe
Central America and the Caribbean	GMT INITIATIVE	17500	wire transfe
Central America and the Caribbean	GMT INITIATIVE	17496	wire transfe
Central America and the Caribbean	GMT INITIATIVE	26594	wire transfe
Central America and the Caribbean	GMT INITIATIVE	17500	wire transfe
East Asia and the Pacific	BASIC RESEARCH	15626	wire transfe
East Asia and the Pacific	BASIC RESEARCH	26043	wire transfe
East Asia and the Pacific	BASIC RESEARCH	10000	wire transfe
East Asia and the Pacific	TREAT ASIA	6330	wire transfe
East Asia and the Pacific	TREAT ASIA	7690	wire transfe
East Asia and the Pacific	TREAT ASIA	25637	wire transfe
East Asia and the Pacific	TREAT ASIA	12250	wire transfe
East Asia and the Pacific	TREAT ASIA	14250	wire transfe
East Asia and the Pacific	TREAT ASIA	19110	wire transfe
East Asia and the Pacific	TREAT ASIA	19050	wire transfe
East Asia and the Pacific	TREAT ASIA	18180	wire transfe
East Asia and the Pacific	TREAT ASIA	8170	wire transfe
East Asia and the Pacific	TREAT ASIA	9150	wire transfe
East Asia and the Pacific	TREAT ASIA	14250	wire transfe
East Asia and the Pacific	TREAT ASIA	132059	wire transfe
East Asia and the Pacific	TREAT ASIA	24042	wire transfe
East Asia and the Pacific	TREAT ASIA	11494	wire transfe
East Asia and the Pacific	TREAT ASIA	16177	wire transfe
East Asia and the Pacific	TREAT ASIA	20529	wire transfe
East Asia and the Pacific	TREAT ASIA	17576	wire transfe
East Asia and the Pacific	TREAT ASIA	21445	wire transfe
East Asia and the Pacific	TREAT ASIA	23404	wire transfe
East Asia and the Pacific	TREAT ASIA	14459	wire transfe
East Asia and the Pacific	TREAT ASIA	7695	wire transfe
East Asia and the Pacific	TREAT ASIA	7087	wire transfe
East Asia and the Pacific	TREAT ASIA	14009	wire transfe
East Asia and the Pacific	TREAT ASIA	15843	wire transfe
East Asia and the Pacific	TREAT ASIA	165747	wire transfe
East Asia and the Pacific	TREAT ASIA	207232	wire transfe
East Asia and the Pacific	TREAT ASIA	243438	wire transfe
East Asia and the Pacific	TREAT ASIA	35051	wire transfe
East Asia and the Pacific	TREAT ASIA	7125	wire transfe
East Asia and the Pacific	TREAT ASIA	5550	wire transfe
East Asia and the Pacific	TREAT ASIA	6525	wire transfe
East Asia and the Pacific	TREAT ASIA	5175	wire transfe
East Asia and the Pacific	TREAT ASIA	7500	wire transfe
East Asia and the Pacific	TREAT ASIA	6450	wire transfe
East Asia and the Pacific	TREAT ASIA	6900	wire transfe
East Asia and the Pacific	TREAT ASIA	7350	wire transfe
East Asia and the Pacific	TREAT ASIA	6300	wire transfe
East Asia and the Pacific	TREAT ASIA	6225	wire transfe
East Asia and the Pacific	TREAT ASIA	19586	wire transfe
East Asia and the Pacific	TREAT ASIA	10499	wire transfe
East Asia and the Pacific	TREAT ASIA	20000	wire transfe
East Asia and the Pacific	TREAT ASIA	15150	wire transfe
East Asia and the Pacific	TREAT ASIA	17524	wire transfe
East Asia and the Pacific	TREAT ASIA	18900	wire transfe
East Asia and the Pacific	TREAT ASIA	15800	wire transfe
East Asia and the Pacific	TREAT ASIA	17850	wire transfe
East Asia and the Pacific	TREAT ASIA	12900	wire transfe
East Asia and the Pacific	TREAT ASIA	20000	wire transfe
East Asia and the Pacific	TREAT ASIA	14775	wire transfe
East Asia and the Pacific	TREAT ASIA	15050	wire transfe
East Asia and the Pacific	TREAT ASIA	20000	wire transfe
East Asia and the Pacific	TREAT ASIA	20000	wire transfe
East Asia and the Pacific	TREAT ASIA	20000	wire transfe
East Asia and the Pacific	TREAT ASIA	20000	wire transfe
East Asia and the Pacific	TREAT ASIA	20000	wire transfe
East Asia and the Pacific	TREAT ASIA	100000	wire transfe
East Asia and the Pacific	TREAT ASIA	6747	wire transfe
East Asia and the Pacific	TREAT ASIA	9433	wire transfe
East Asia and the Pacific	BASIC RESEARCH	286064	wire transfe
East Asia and the Pacific	TREAT ASIA	34622	wire transfe
East Asia and the Pacific	TREAT ASIA	41667	wire transfe
East Asia and the Pacific	TREAT ASIA	36098	wire transfe
East Asia and the Pacific	TREAT ASIA	150000	wire transfe
East Asia and the Pacific	TREAT ASIA	19833	wire transfe
East Asia and the Pacific	TREAT ASIA	6000	wire transfe
East Asia and the Pacific	TREAT ASIA	6150	wire transfe
East Asia and the Pacific	TREAT ASIA	9453	wire transfe
East Asia and the Pacific	TREAT ASIA	26775	wire transfe
East Asia and the Pacific	TREAT ASIA	19042	wire transfe
East Asia and the Pacific	TREAT ASIA	11315	wire transfe
East Asia and the Pacific	GMT INITIATIVE	18000	wire transfe
East Asia and the Pacific	GMT INITIATIVE	17000	wire transfe
East Asia and the Pacific	GMT INITIATIVE	18135	wire transfe
East Asia and the Pacific	TREAT ASIA	15167	wire transfe
East Asia and the Pacific	TREAT ASIA	40000	wire transfe
East Asia and the Pacific	TREAT ASIA	15964	wire transfe
East Asia and the Pacific	TREAT ASIA	15000	wire transfe
East Asia and the Pacific	TREAT ASIA	5625	wire transfe
East Asia and the Pacific	TREAT ASIA	5625	wire transfe
East Asia and the Pacific	TREAT ASIA	5625	wire transfe
East Asia and the Pacific	TREAT ASIA	11250	wire transfe
East Asia and the Pacific	TREAT ASIA	11250	wire transfe
East Asia and the Pacific	TREAT ASIA	15000	wire transfe
East Asia and the Pacific	TREAT ASIA	11250	wire transfe
East Asia and the Pacific	TREAT ASIA	15000	wire transfe
East Asia and the Pacific	TREAT ASIA	79118	wire transfe
East Asia and the Pacific	TREAT ASIA	15000	wire transfe
East Asia and the Pacific	TREAT ASIA	9820	wire transfe
East Asia and the Pacific	TREAT ASIA	5650	wire transfe
East Asia and the Pacific	TREAT ASIA	14702	wire transfe
East Asia and the Pacific	TREAT ASIA	39029	wire transfe
Europe (Including Iceland and Greenland)	BASIC RESEARCH	26043	wire transfe
Europe (Including Iceland and Greenland)	BASIC RESEARCH	39062	wire transfe
Europe (Including Iceland and Greenland)	BASIC RESEARCH	10000	wire transfe
Europe (Including Iceland and Greenland)	BASIC RESEARCH	90765	wire transfe
Europe (Including Iceland and Greenland)	BASIC RESEARCH	159732	wire transfe
Europe (Including Iceland and Greenland)	BASIC RESEARCH	120000	wire transfe
Europe (Including Iceland and Greenland)	BASIC RESEARCH	120000	wire transfe
Europe (Including Iceland and Greenland)	PUBLIC POLICY	20000	wire transfe
Europe (Including Iceland and Greenland)	GMT INITIATIVE	14280	wire transfe
Europe (Including Iceland and Greenland)	GMT INITIATIVE	12000	wire transfe
Europe (Including Iceland and Greenland)	GMT INITIATIVE	14920	wire transfe
Europe (Including Iceland and Greenland)	GMT INITIATIVE	15000	wire transfe
Europe (Including Iceland and Greenland)	GMT INITIATIVE	20000	wire transfe
Middle East and North Africa	GMT INITIATIVE	20000	wire transfe
North America	GMT INITIATIVE	20000	wire transfe
North America	PREVENTION SCIENCE OUTREACH	130000	wire transfe
Russia and the Newly Independent States	GMT INITIATIVE	12000	wire transfe
Russia and the Newly Independent States	GMT INITIATIVE	14982	wire transfe
Russia and the Newly Independent States	GMT INITIATIVE	15050	wire transfe
Russia and the Newly Independent States	GMT INITIATIVE	14995	wire transfe
Russia and the Newly Independent States	GMT INITIATIVE	19952	wire transfe
Russia and the Newly Independent States	GMT INITIATIVE	20200	wire transfe
South America	GMT INITIATIVE	20000	wire transfe
South America	GMT INITIATIVE	20000	wire transfe
South America	GMT INITIATIVE	20000	wire transfe
South America	GMT INITIATIVE	20000	wire transfe
South America	GMT INITIATIVE	19900	wire transfe
South America	GMT INITIATIVE	19859	wire transfe
South America	GMT INITIATIVE	20000	wire transfe
South America	GMT INITIATIVE	14440	wire transfe
South America	GMT INITIATIVE	15000	wire transfe
South America	GMT INITIATIVE	17494	wire transfe
South America	GMT INITIATIVE	24066	wire transfe
South America	PREVENTION SCIENCE OUTREACH	35000	wire transfe
South Asia	GMT INITIATIVE	11959	wire transfe
South Asia	TREAT ASIA	13931	wire transfe
South Asia	TREAT ASIA	18750	wire transfe
South Asia	TREAT ASIA	18750	wire transfe
South Asia	TREAT ASIA	5625	wire transfe
Sub-Saharan Africa	GMT INITIATIVE	20000	wire transfe
Sub-Saharan Africa	GMT INITIATIVE	15000	wire transfe
Sub-Saharan Africa	GMT INITIATIVE	20000	wire transfe
Sub-Saharan Africa	GMT INITIATIVE	18500	wire transfe
Sub-Saharan Africa	GMT INITIATIVE	22000	wire transfe
Sub-Saharan Africa	GMT INITIATIVE	20000	wire transfe
Sub-Saharan Africa	GMT INITIATIVE	19789	wire transfe
Sub-Saharan Africa	GMT INITIATIVE	19980	wire transfe
Sub-Saharan Africa	GMT INITIATIVE	20000	wire transfe
Sub-Saharan Africa	GMT INITIATIVE	20000	wire transfe
Sub-Saharan Africa	GMT INITIATIVE	19984	wire transfe
Sub-Saharan Africa	GMT INITIATIVE	20000	wire transfe
Sub-Saharan Africa	GMT INITIATIVE	20000	wire transfe
Sub-Saharan Africa	GMT INITIATIVE	10000	wire transfe
Sub-Saharan Africa	GMT INITIATIVE	26000	wire transfe
Sub-Saharan Africa	PUBLIC POLICY	60000	wire transfe

Field	Value	IRS element (for citing)
Total Number Of501c3 Orgs	159	TotalNumberOf501c3Orgs
Transfer To Foreign Corp	false	TransferToForeignCorp
Interest In Foreign Trust	false	InterestInForeignTrust
Own Foreign Corp	false	OwnForeignCorp
Passive Foreign Invest Co	false	PassiveForeignInvestCo
Foreign Partnership	false	ForeignPartnership
Boycott Countries	false	BoycottCountries

Form990 Schedule F Part V Form990ScheduleFPartV (3 entries)

IdentifierIdentifier	Return ReferenceReturnReference	ExplanationExplanation
Foreign Activities	Part I, Line 2	International organizations are recommended for funding based upon the results of community-based peer review and/or program staff assessment of proposal merit and organization capacity to undertake proposed projects that are CHARITABLE in purpose. Pre-award due-diligence for new international grantees includes review of organization documents and registrations to verify that the organization operates for a CHARITABLE purpose and that basic capacity for project oversight and governance has been established. All international grantees are required to report semi-annually on project progress and expenditures; continued reporting is required until such time as grant funds are expended in full. Reports are reviewed by administrative and program staff. Additional oversight is provided as necessary by means of ongoing, informal contact with sites regarding progress and technical issues and site visits where feasible. International research grant recipients submit an interim and a final progress reporting addition to expenditures reports due following the ends of the 2nd, 3rd and final quarters of the performance period.
foreign activities	Part I, Line 3, Column D	The Foundation for AIDS Research conducts many of its grant-making program services (see Part III of Form 990) in U.S. and foreign jurisdictions. In column D, the organization has reported the basic program these grants support; please refer to Part III for more information about these programs/initiatives.
Foreign Activities - Status of Grantees		The Foundation for Aids Research supports many non-U.S. organizations in the fight against AIDS and HIV-related diseases. For purposes of Schedule F, Part II, Line 2 - all 159 charities supported are presumed to be the equivalent of U.S. charities.

Schedule G IRS990ScheduleG

Field	Value	IRS element (for citing)
Mail Solicitations	X	MailSolicitations
Email Solicitations	X	EmailSolicitations
Phone Solicitations	X	PhoneSolicitations
Solicitation Of Non Govt Grants	X	SolicitationOfNonGovtGrants
Solicitation Of Govt Grants	X	SolicitationOfGovtGrants
Special Fundraising Events	X	SpecialFundraisingEvents
Agreement Ref Fundraising	true	AgreementRefFundraising

Fundraiser Activity Information FundraiserActivityInformation (6 entries)

Name Of IndividualNameOfIndividual	Address Line1AddressUS/AddressLine1	Address Line2AddressUS/AddressLine2	CityAddressUS/City	StateAddressUS/State	ZIP CodeAddressUS/ZIPCode	ActivityActivity	Fundraiser Control Of FundsFundraiserControlOfFunds	Gross ReceiptsGrossReceipts	Amount Retained By ContractorAmountRetainedByContractor	Net To OrganizationNetToOrganization
aab productions	387 Grant Street	Suite K705	New York	NY	10002	Fundraising Event/Prod	false	17864320	245067	17619253
john mini consulting inc	707 Savannah Road		Lewes	DE	199581521	direct mail	false	1731016	95150	1635866
public interest communications	7700 Leesburg Pike		Falls Church	VA	22043	tele marketing	false	54024	70572	-16548
Eidolon Communications INc	15 Maiden Lane Suite 1401		New York	NY	10038	DIRECT MAIL	false	199443	47700	151743
telefund inc	PO Box 120557		Boston	MA	02111	tele marketing	false	18868	16231	2637
sanky communications inc	589 Eight Avenue 10th Floor		New York	NY	10018	counseling	false	417841	102434	315407

Field	Value	IRS element (for citing)
Total Gross Receipts	20285512	TotalGrossReceipts
Total Retained By Contractors	577154	TotalRetainedByContractors
Total Net To Organization	19708358	TotalNetToOrganization
Licensed States	AL	LicensedStates
Licensed States	AK	LicensedStates
Licensed States	AZ	LicensedStates
Licensed States	AR	LicensedStates
Licensed States	CA	LicensedStates
Licensed States	CO	LicensedStates
Licensed States	CT	LicensedStates
Licensed States	DC	LicensedStates
Licensed States	FL	LicensedStates
Licensed States	GA	LicensedStates
Licensed States	HI	LicensedStates
Licensed States	IL	LicensedStates
Licensed States	KS	LicensedStates
Licensed States	KY	LicensedStates
Licensed States	LA	LicensedStates
Licensed States	ME	LicensedStates
Licensed States	MD	LicensedStates
Licensed States	MA	LicensedStates
Licensed States	MI	LicensedStates
Licensed States	MN	LicensedStates
Licensed States	MS	LicensedStates
Licensed States	MO	LicensedStates
Licensed States	NH	LicensedStates
Licensed States	NJ	LicensedStates
Licensed States	NM	LicensedStates
Licensed States	NY	LicensedStates
Licensed States	NC	LicensedStates
Licensed States	ND	LicensedStates
Licensed States	OH	LicensedStates
Licensed States	OK	LicensedStates
Licensed States	OR	LicensedStates
Licensed States	PA	LicensedStates
Licensed States	RI	LicensedStates
Licensed States	SC	LicensedStates
Licensed States	TN	LicensedStates
Licensed States	TX	LicensedStates
Licensed States	UT	LicensedStates
Licensed States	VA	LicensedStates
Licensed States	WA	LicensedStates
Licensed States	WV	LicensedStates
Licensed States	WI	LicensedStates

Events Information EventsInformation

Field	Value	IRS element (for citing)
Name Of Event1	Cannes	NameOfEvent1
Gross Receipts Event1	12526496	GrossReceiptsEvent1
Charitable Contributions Event1	12085496	CharitableContributionsEvent1
Gross Revenue Event1	441000	GrossRevenueEvent1
Cash Prizes Event1	0	CashPrizesEvent1
Non Cash Prizes Event1	0	NonCashPrizesEvent1
Rent Facility Costs Event1	746885	RentFacilityCostsEvent1
Food And Beverage Event1	543201	FoodAndBeverageEvent1
Other Direct Expenses Event1	3422020	OtherDirectExpensesEvent1
Name Of Event2	Dallas	NameOfEvent2
Gross Receipts Event2	4507778	GrossReceiptsEvent2
Charitable Contributions Event2	4407378	CharitableContributionsEvent2
Gross Revenue Event2	100400	GrossRevenueEvent2
Cash Prizes Event2	0	CashPrizesEvent2
Non Cash Prizes Event2	0	NonCashPrizesEvent2
Rent Facility Costs Event2	46894	RentFacilityCostsEvent2
Food And Beverage Event2	156114	FoodAndBeverageEvent2
Other Direct Expenses Event2	2273065	OtherDirectExpensesEvent2
Total Number Of Other Events	14	TotalNumberOfOtherEvents
Gross Receipts Other Events	10408684	GrossReceiptsOtherEvents
Charitable Contrib Other Events	9592884	CharitableContribOtherEvents
Gross Revenue Other Events	815800	GrossRevenueOtherEvents
Cash Prizes Other Events	0	CashPrizesOtherEvents
Non Cash Prizes Other Events	0	NonCashPrizesOtherEvents
Rent Facility Costs Other Events	744868	RentFacilityCostsOtherEvents
Food And Beverage Other Events	228413	FoodAndBeverageOtherEvents
Other Direct Expenses Other Events	3054905	OtherDirectExpensesOtherEvents
Gross Receipts Total	27442958	GrossReceiptsTotal
Charitable Contributions Total	26085758	CharitableContributionsTotal
Gross Revenue Total Events	1357200	GrossRevenueTotalEvents
Cash Prizes Total Events	0	CashPrizesTotalEvents
Non Cash Prizes Total Events	0	NonCashPrizesTotalEvents
Rent Facility Costs Total Events	1538647	RentFacilityCostsTotalEvents
Food And Beverage Total Events	927728	FoodAndBeverageTotalEvents
Other Direct Expenses Total Events	8749990	OtherDirectExpensesTotalEvents
Direct Expense Summary Events	11216365	DirectExpenseSummaryEvents
Net Income Summary	-9859165	NetIncomeSummary

Form990 Schedule G Part IV Form990ScheduleGPartIV

Field	Value	IRS element (for citing)
Identifier	Schedule G, Part I	Identifier
Explanation	The Foundation for AIDS Research actually paid out $470,337 in fundraising expenses for the year ending September 30, 2013. This amount is reported on Part IX, Line 11(e). For purposes of Schedule G, the Foundation is reporting all amounts paid to the consultants listed on Part I, regardless of whether such amounts were pure fundraising expenses or event production costs. On Schedule G, the total amount paid to the organizations listed is $577,154. Of that $577,154, only $470,337 was paid for fundraising services, the remaining $106,817 was paid for event production services. In the interests of clarity, the foundation would also like to make clear that the compensation reported as having been paid to the professional fundraisers reported on Schedule G is reported on a fiscal year basis. Some of those same fundraisers are reported on the foundation's top 5 highest paid independent contractors list (in Schedule O). In compliance with the instructions to the Form 990, compensation reported for Part VII (and listed in Schedule O) is reported on a calendar year basis. Accordingly, amounts on Part VII and Schedule G will not reconcile.	Explanation

Schedule I IRS990ScheduleI

Field	Value	IRS element (for citing)
Records Maintained	true	RecordsMaintained

Recipient Table RecipientTable (51 entries)

Address Line1AddressUS/AddressLine1	CityAddressUS/City	StateAddressUS/State	ZIP CodeAddressUS/ZIPCode	EIN Of RecipientEINOfRecipient	IRC SectionIRCSection	Amount Of Cash GrantAmountOfCashGrant	Purpose Of GrantPurposeOfGrant
The Aaron Diamond AIDS Research Center
455 First Avenue 7th Floor	New York	NY	10016	133540234	501(c)(3)	15626	BASIC RESEARCH
University of California Los Angeles
11000 Kinross Avenue Suite 102	Los Angeles	CA	900951406	956006143	501(c)(3)	7143	BASIC RESEARCH
University of California San Francisco
333 California Street Suite 315	San Francisco	CA	94118	946036493	501(c)(3)	72000	BASIC RESEARCH
Case Western Reserve University School of Medicin
10900 Euclid Avenue	Cleveland	OH	44106	341018992	501(c)(3)	62479	BASIC RESEARCH
Aaron Diamond AIDS Research Center
455 First Avenue 7th Floor	New York	NY	10016	133540234	501(c)(3)	62502	BASIC RESEARCH
New England Primate Research Center Harvard Medic
Harvard Medical School 25 Shattuck	Southborough	MA	01772	042103580	501(c)(3)	62502	BASIC RESEARCH
University of California San Francisco
533 Parnassus Avenue U442	San Francisco	CA	94110	946036493	501(c)(3)	10000	BASIC RESEARCH
University of California San Francisco
3333 California Street Suite 315	San Francisco	CA	94110	946036493	501(c)(3)	10000	BASIC RESEARCH
University of California San Francisco
3333 California Street Suite 315	San Francisco	CA	94110	946036493	501(c)(3)	10000	BASIC RESEARCH
Johns Hopkins University School of Medicine
733 North Boradway Suite 117	Baltimore	MD	21287	520595110	501(c)(3)	10000	BASIC RESEARCH
Case Western Reserve University
10900 Euclid Avenue	Cleveland	OH	44106	341018992	501(c)(3)	10000	BASIC RESEARCH
The Salk Institute for Biological Studies
10010 North Torrey Pines Road	La Jolla	CA	92037	952160097	501(c)(3)	10000	BASIC RESEARCH
Vaccine and Gene Therapy Institute of Florida
11350 SW Village Parkway	Port St Lucie	FL	34987	364631835	501(c)(3)	62502	BASIC RESEARCH
University of Washington
4333 Brooklyn Avenue NE Box 35947	Seattle	WA	981959472	916001537	501(c)(3)	62502	BASIC RESEARCH
Vaccine and Gene Therapy Institute of Florida
11350 SW Village Parkway 3rd Floor	Port St Lucie	FL	34987	364631835	501(c)(3)	62502	BASIC RESEARCH
Case Western Reserve University
10900 Euclid Avenue LC 4930	Cleveland	OH	44106	341018992	501(c)(3)	62502	BASIC RESEARCH
Beth Israel Medical Center
Dazian Building First Avenue at 16	New York	NY	10003	135564934	501(c)(3)	37646	PUBLIC POLICY
California Institute of Technology
1200 E California Blvd	Pasadena	CA	91125	951643307	501(c)(3)	124800	BASIC RESEARCH
Case Western Reserve University
10900 Euclid Avenue	Cleveland	OH	44106	341018992	501(c)(3)	124998	BASIC RESEARCH
Massachusetts General Hospital
55 Fruit Street	Boston	MA	02114	042697983	501(c)(3)	124998	BASIC RESEARCH
Beth Israel Medical Center - Edmond de Rothschild
First Avenue at 16th Street	New York	NY	10003	135564934	501(c)(3)	22500	PUBLIC POLICY
Tulane University
1430 Tulane Avenue EP-15	New Orleans	LA	70112	720423889	501(c)(3)	33333	BASIC RESEARCH
John Hopkins University
Office of Research Administration	Baltimore	MD	21205	520595110	501(c)(3)	80000	BASIC RESEARCH
John Hopkins University
Office of Research Administration	Baltimore	MD	21205	520595110	501(c)(3)	80000	BASIC RESEARCH
The Brigham and Women's Hospital Inc
75 Francis Street	Boston	MA	02115	042312909	501(c)(3)	96397	BASIC RESEARCH
University of North Carolina at Chapel Hill
104 Airport Drive Suite 2200 CB	Chapel Hill	NC	27599	566001393	501(c)(3)	166748	BASIC RESEARCH
Johns Hopkins University
733 North Broadway Suite 117	Baltimore	MD	21205	520595110	501(c)(3)	351225	BASIC RESEARCH
Global Health Committee Inc
200 Longwood Avenue	Boston	MA	02115	043481920	501(c)(3)	297749	TREAT ASIA
Johns Hopkins University School of Medicine
733 N Broadway Street Broadway Res	Baltimore	MD	21201	520595110	501(c)(3)	46872	BASIC RESEARCH
Fred Hutchinson Cancer Research Center
1100 Fairview Ave N C2-187	Seattle	WA	98109	237156071	501(c)(3)	46872	BASIC RESEARCH
Dana-Farber Cancer Institute Inc
450 Brookline Avenue CLS 1017	Boston	MA	02215	042263040	501(c)(3)	46872	BASIC RESEARCH
The Scripps Research Institute
10550 North Torrey Pines Road	La Jolla	CA	92037	330435954	501(c)(3)	46872	BASIC RESEARCH
Veterans Medical Research Foundation
3350 La Jolla Village Drive MC 151	San Diego	CA	92161	330189397	501(c)(3)	120000	BASIC RESEARCH
Universiy of Washington
4333 Brooklyn Ave NE Box 359472	Seattle	WA	981959472	916001537	501(c)(3)	120000	BASIC RESEARCH
University of California San Francisco
3333 California Street Suite 315	San Francisco	CA	94110	946036493	501(c)(3)	114162	BASIC RESEARCH
Harvard Medical School
25 Shattuck Street	Southborough	MA	01772	042103580	501(c)(3)	119200	BASIC RESEARCH
Oregon Health and Science University
3181 SW Sam Jackson Park Rd	Portland	OR	97239	931176109	501(c)(3)	120000	BASIC RESEARCH
Vaccine & Gene Therapy Institute Florida
9801 SW Discovery Way	Port St Lucie	FL	34987	364631835	501(c)(3)	119990	BASIC RESEARCH
Baron Edmond de Rothschild Chemical Dep
First Avenue at 16th Street	New York	NY	10003	135564934	501(c)(3)	67500	PUBLIC POLICY
AIDS Foundation of Chicago as sponsor of Internati
200 West Jackson Ste 2200	Chicago	IL	60606	363412054	501(c)(3)	7500	GMT INITIATIVE
Northwestern University
750 N Lake Shore Drive	Chicago	IL	60611	362167817	501(c)(3)	5850	BASIC RESEARCH
Johns Hopkins University Bloomberg School of Publi
615 N Wolfe St	Baltimore	MD	21205	520595110	501(c)(3)	48500	GMT INITIATIVE
Johns Hopkins University Bloomberg School of Publi
615 N Wolfe St	Baltimore	MD	21205	520595110	501(c)(3)	15107	GMT INITIATIVE
Case Western Reserve University
10900 Euclid Ave	Cleveland	OH	44106	341018992	501(c)(3)	116655	BASIC RESEARCH
Vaccine and Gene Therapy Institute Florida
9801 SW Discovery Way	Port St Lucie	FL	34987	364631835	501(c)(3)	196761	BASIC RESEARCH
University of California Los Angeles
11000 Kinross Avenue Suite 211 MC	Los Angeles	CA	90095	956006143	501(c)(3)	100000	BASIC RESEARCH
Johns Hopkins University
733 N Broadway Office of Research	Baltimore	MD	21205	520595110	501(c)(3)	60000	BASIC RESEARCH
Johns Hopkins University School of Medicine
733 North Broadway Street	Baltimore	MD	21205	520595110	501(c)(3)	20001	BASIC RESEARCH
Worldwide Orphans Foundation
515 Valley Street Suite 201	Maplewood	NJ	07040	133968225	501(c)(3)	14927	TREAT ASIA
Blood Systems Inc dba Blood Systems Research Ins
270 Masonic Avenue	San Francisco	CA	941184417	860098929	501(c)(3)	42193	BASIC RESEARCH
University of Pittsburgh
123 University Place	Pittsburgh	PA	152132303	250965591	501(c)(3)	102000	GMT INITIATIVE

Field	Value	IRS element (for citing)
Total Nbr Of501 C3 And Govt Grants	51	TotalNbrOf501C3AndGovtGrants

Form990 Schedule I Part IV Form990ScheduleIPartIV

Field	Value	IRS element (for citing)
Identifier	Grants and Assistance	Identifier
Return Reference	Part I, Line 2	ReturnReference
Explanation	amfAR provides grants and fellowships to independent not-for-profit organizations through a peer-review process. Grant applications are first reviewed by the Foundation's volunteer scientific advisory committee, which comprises recognized experts in the medical, scientific, and social sciences disciplines relevant to HIV and AIDS. The scientific advisory committee then sends its evaluations to one of the three committees (research, global initiatives or public policy) of the Foundation's program board, which serves in an advisory capacity to the Board of Trustees. After a program committee has completed its review of the applications, it presents its funding recommendations to amfAR's executive committee and/or the full Board of Trustees for final approval and funding authorization. Grants and fellowships are payable over a one-to-three-year period, and are revocable at amfAR's option if the recipient's performance or use of funds is not consistent with the terms of the grant or fellowships. In certain cases, the actual amounts paid under grants and fellowship awards may be less than the original award if the recipient does not use the full amount awarded. Therefore, a reserve for unexpended grants and fellowships has been recorded. Subawards are grants awarded to not-for-profit organizations to support the costs of collaboration and participation in HIV/AIDS-related research projects for which amfAR has secured restricted funds. Subawards are payable over a one-year period, although advance payments, in full or in part, may be issued following execution of the subaward agreement. Subawards are contingent upon the availability of funds and are revocable if the recipients' performance or use of funds is not consistent with the subaward terms.	Explanation

Schedule J IRS990ScheduleJ

Field	Value	IRS element (for citing)
Compensation Committee	X	CompensationCommittee
Independent Consultant	X	IndependentConsultant
Compensation Survey	X	CompensationSurvey
Board Or Committee Approval	X	BoardOrCommitteeApproval
Severance Payment	false	SeverancePayment
Supplemental Nonqual Retire Plan	true	SupplementalNonqualRetirePlan
Equity Based Comp Arrangement	false	EquityBasedCompArrangement
Comp Based On Revenue Of Filing Org	false	CompBasedOnRevenueOfFilingOrg
Comp Based On Revenue Related Orgs	false	CompBasedOnRevenueRelatedOrgs
Comp Based Net Earnings Filing Org	false	CompBasedNetEarningsFilingOrg
Comp Based Net Earnings Relate Orgs	false	CompBasedNetEarningsRelateOrgs
Any Non Fixed Payments	false	AnyNonFixedPayments
Initial Contract Exception	false	InitialContractException

Form990 Schedule J Part II Form990ScheduleJPartII (14 entries)

TitleTitle	Base Compensation Filing OrgBaseCompensationFilingOrg	Comp Based On Related OrgsCompBasedOnRelatedOrgs	Bonus Filing OrgBonusFilingOrg	Bonus Related OrgsBonusRelatedOrgs	Other Compensation Filing OrgOtherCompensationFilingOrg	Other Compensation Related OrgsOtherCompensationRelatedOrgs	Deferred Comp Filing OrgDeferredCompFilingOrg	Deferred Comp Related OrgsDeferredCompRelatedOrgs	Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrg	Nontaxable Benefits Related OrgsNontaxableBenefitsRelatedOrgs	Total Compensation Filing OrgTotalCompensationFilingOrg	Total Compensation Related OrgsTotalCompensationRelatedOrgs
Kevin Frost
Chief Executive Officer	385700	0	0	0	0	0	69500	0	28683	0	483883	0
Bradley Jensen
ASST Treasurer, CFO	217845	0	0	0	0	0	15470	0	31319	0	264634	0
John F Logan JD PhD
ASST Secretary, VP & GC	203482	0	0	0	0	0	14331	0	10201	0	228014	0
Rowena Johnston
ASST Secretary, VP OF RESEARCH	166901	0	0	0	0	0	11736	0	10201	0	188838	0
Edward Donnelly
ASST Treasurer, ControlleR	133796	0	0	0	0	0	9796	0	9043	0	152635	0
Gregory L Boroff
Vice President of Development	228217	0	0	0	0	0	16218	0	10201	0	254636	0
Christopher Collins
Vice President, Public Policy	192518	0	0	0	0	0	12720	0	19636	0	224874	0
Annette Sohn
Vice President, TREAT Asia	200613	0	0	0	0	0	14082	0	5553	0	220248	0
Eric Muscatell
Director, Philanthropy	157089	0	0	0	0	0	11276	0	10201	0	178566	0
Andrew McInnes
Director, Publications	134850	0	0	0	0	0	9876	0	31319	0	176045	0
Anthony Ancona
Vice President, Human Resource	155133	0	0	0	0	0	10935	0	3276	0	169344	0
Susan Doster
Chief Technology Officer	132775	0	0	0	0	0	9277	0	10201	0	152253	0
AnnMarie Shannahan
Vice President, Public Info	194344	0	0	0	0	0	13671	0	10201	0	218216	0
Bennah Serfaty
Senior Dir. of Communications	120255	0	0	0	0	0	7992	0	31319	0	159566	0

Form990 Schedule J Part III Form990ScheduleJPartIII

Field	Value	IRS element (for citing)
Identifier	Compensation	Identifier
Return Reference	Part I, Line 4	ReturnReference
Explanation	Chief Executive Officer, Kevin Frost, participated in a supplemental nonqualified retirement plan; however, he did not receive a distribution in 2013.	Explanation

Schedule M IRS990ScheduleM

Works Of Art WorksOfArt

Field	Value	IRS element (for citing)
Non Cash Checkbox	X	NonCashCheckbox
Number Of Contributions	1	NumberOfContributions
Noncash Contribs Rptd F990	56250	NoncashContribsRptdF990
Method Of Determining Revenues	appraisal	MethodOfDeterminingRevenues

Field	Value	IRS element (for citing)
Art Historical Treasures		ArtHistoricalTreasures
Art Fractional Interest		ArtFractionalInterest
Books And Publications		BooksAndPublications
Clothing And Household Goods		ClothingAndHouseholdGoods
Cars And Other Vehicles		CarsAndOtherVehicles
Boats And Planes		BoatsAndPlanes
Intellectual Property		IntellectualProperty

Securities Publicly Traded SecuritiesPubliclyTraded

Field	Value	IRS element (for citing)
Non Cash Checkbox	X	NonCashCheckbox
Number Of Contributions	14	NumberOfContributions
Noncash Contribs Rptd F990	47853	NoncashContribsRptdF990
Method Of Determining Revenues	sales price	MethodOfDeterminingRevenues

Field	Value	IRS element (for citing)
Securities Closely Held Stock		SecuritiesCloselyHeldStock
Securities Prtnrshp Trust Intrsts		SecuritiesPrtnrshpTrustIntrsts
Securities Miscellaneous		SecuritiesMiscellaneous
Qualified Contrib Hist Struct		QualifiedContribHistStruct
Qualified Contrib Other		QualifiedContribOther
Real Estate Residential		RealEstateResidential
Real Estate Commercial		RealEstateCommercial
Real Estate Other		RealEstateOther
Collectibles		Collectibles
Food Inventory		FoodInventory
Drugs And Medical Supplies		DrugsAndMedicalSupplies
Taxidermy		Taxidermy
Historical Artifacts		HistoricalArtifacts
Scientific Specimens		ScientificSpecimens
Archaeological Artifacts		ArchaeologicalArtifacts
Any Property That Must Be Held	false	AnyPropertyThatMustBeHeld
Review Process Unusual NC Gifts	true	ReviewProcessUnusualNCGifts
Third Parties Used	true	ThirdPartiesUsed

Form990 Schedule M Part II Form990ScheduleMPartII

Field	Value	IRS element (for citing)
Identifier	Form 990, Schedule M	Identifier
Explanation	Line 31: To the extent that amFAR receives non-standard contributions, the organization's policy is to liquidate those items into cash for eventual use in support of the organization's mission. Line 32A: When the organization receives contributions of securities, it uses its investment broker to liquidate those holdings to fund amFAR's various research program activities.	Explanation

Schedule O IRS990ScheduleO

General Explanation GeneralExplanation (10 entries)

IdentifierIdentifier	Return ReferenceReturnReference	ExplanationExplanation
Program Service Accomplishments(1)	Part III, Line 4a-4d(1)	Line 4a: Research: amfAR supports research projects that explore novel approaches to scientifically sound but untested hypotheses in all areas of research on HIV/AIDS, funding goal-oriented studies that often lack the preliminary data required for support from traditional grant-makers. The Foundation plays a vital role in HIV/AIDS research, identifying critical gaps in knowledge and providing essential seed money that enables grantees and fellows to test the merits of new concepts or technologies that subsequently can be validated through large-scale studies, such as those funded by the National Institutes of Health. amfAR fellowships allow talented young investigators to conduct original investigations under the guidance of experienced scientists, helping to ensure the long-term vitality of AIDS research. Grants and fellowships are awarded through a rigorous process of peer review by a team of independent HIV/AIDS experts drawn largely from the volunteer scientists on amfAR's Scientific Advisory Committee. Guided by its scientific advisors and with the approval of its board of trustees, amfAR pursues a strategic research plan that focuses on the treatment, prevention, and cure of HIV/AIDS. In 2013, amFAR awarded nearly $4 million in grants and fellowships to support 20 research projects. Cure-Focused Studies The Search for a cure for HIV/AIDS is at the center of amFAR's research efforts. In 2013, through the amFAR Research Consortium on HIV Eradication (ARCHE) program-now in its fourth year of funding-and other targeted grants, the Foundation awarded nearly $3 million for cure-focused research. First Child Cured of HIV At the Conference on Retroviruses and Opportunistic Infections in March 2013, Dr. Deborah Persaud of John Hopkins Children's Center detailed the case of a two-year-old child in Mississippi who had been cured of HIV. Confirmation of the cure was made possible by a grant amFAR awarded to Dr. Persaud and her colleague Dr. Katherine Luzuriaga of the University of Massachusetts Medical School in September 2012. The grant allowed them to establish a research collaboratory to explore and document possible pediatric HIV cure cases. amFAR Research Consortium on HIV Eradication The Foundation launched the ARCHE program in 2010 as a way to leverage the expertise and innovation of distinguished scientists from across the globe to advance cure-focused research. In July, more than $1.4 million in funding went to four collaborative teams of researchers working in the United States, the United Kingdom, France, Thailand, and Australia on studies exploring potential strategies for eliminating HIV infection from the body and characterizing viral reservoirs-which present a major obstacle to a cure. One study, led by Dr. Eric Arts of Case Western Reserve University in Cleveland, Ohio, aims to develop and test a vaccine-like HIV treatment specific to each patient's virus. Unlike other approaches toward an HIV cure that focus on inducing cell changes in all cells that are vulnerable to HIV infection, this treatment specifically targets the infected cells lying dormant in teh viral reservoir. Dr. Arts and Dr. Yong Gao from Case Western is working wiht Drs. Robin Shattock, Sarah Fidler, and Caroline Foster of Imperial College London to study the treatment's effectiveness. In another study, a team led by Dr. Nicolas Chomont of the Vaccine and Gene Therapy Institute in Port St. Lucie, Florida, is studying HIV persistence in T cell subsets during antiretroviral therapy (ART). Specifically, they are investigating the subsets of CD4+ T memory cells-the cells where the HIV reservoir mainly resides-and the roles they may play as a potential target for a cure. Dr. Chomont is working in collaboration with three-time ARCHE grantees Dr. Darah Palmer of University of Sydney, Australia, and Dr. Steven Deeks of the University of California, San Francisco (UCSF); Dr. Jintanat Ananworanich from the Red Cross AIDS Research Centre in Bangkok, Thailand; and Dr. Asier Saez-Cirion of Institut Pasteur in Paris, France. Targeted Grants for HIV Cure Research In February 2013, amfAR awarded eight targeted grants totaling more than $1.4 million to leading researchers from around the world who are working on a variety of cutting-edge, cure-focused studies. These projects include research aimed at therapeutic vaccine development, expanding our understanding of latent viral reservoirs, and examining pharmacological and gene therapy approaches to curing HIV. Dr. Jonah Sacha of the Oregon Health and Science University, in Portland, is examining the macrophage-an immune cell that is closely related to the T cell-for its potential role in maintaining hidden reservoirs of HIV. Dr. Sacha and colleagues propose to directly assess the function of macrophages in viral persistence in a non-human primate model of AIDS. Understanding the macrophage's contribution will guide future approaches to eliminating residual viral reservoirs.
Program Service Accomplishments(2)	Part III, Line 4a-4d (2)	Line 4a, Continued: Although the immune system can greatly reduce levels of virus after infection, it cannot maintain this control indefinitely. Therapeutic vaccines, which are currently being designed and tested, may enable patients to stop taking ART without progressing to disease. Dr. Christian Brander at Irsicaixa AIDS Research Institute, Badalona, Spain, and his colleagues plan to closely monitor changes in immune function after patients-who are currently enrolled in a therapeutic vaccine clinical trial-stop taking their anti-HIV medication. Their findings will help guide the design of more effective therapeutic vaccines and may also enable researchers to predict which individuals will respond best in future trials. Therapeutic vaccines may one day play an important role in achieving sustained remission of HIV. Another study, led by Dr. Satish Pillai at UCSF is examining how an unusual genetic mutation-CCR5-delta32-may enhance the curability of HIV. He will measure the amount of virus that persists in patients with or without this mutation. Applying cutting-edge laboratory techniques, Dr. Pillai's team will compare the size, composition, and decay of the HIV-1 latent reservoir in individuals with and without the mutation. Gene therapy approaches are being investigated as a means of curing HIV. One strategy that has shown promising results uses a gene therapy method to modify a patient's own cells in the laboratory to make them resistant to virus infection. Dr. Rafick-Pierre Skaly, at the Vaccine and Gene Therapy Institute in Port St. Lucie, Florida, will build on the current work being done using this approach to determine if virus becomes undetectable in the blood after stopping ART. He will monitor immune responses, inflammation, and viral reservoirs in a group of patients to ascertain the long-term benefit of this therapy and factors that can improve outcomes of gene therapy and other strategies to cure HIV. Mathilde Krim Fellowships Four researchers received Mathilde Krim Fellowships in Basic Biomedical Research, an initiative that provides funding for exceptional young researchers who are new to the field of HIV/AIDS research. The initiative has already achieved spectacular results, including numerous published studies in major scientific journals. The 2013 Krim Fellows-each of whom received $125,000-are working on projects focused on HIV/AIDS cure and epidemiological research and vaccine and treatment development. Among the 2013 fellows is Dr. Leopold Kong, Ph.D., of the Scripps Research Institute in California, who will attempt to develop a vaccine using the protective coating of sugar-like molecules that surround the virus. This coating is traditionally thought to hamper the development of antibodies that might form the basis of a vaccine. Dr. Kong will determine whether this protective coat can instead be turned against the virus to render it vulnerable to destruction by the body's immune system. His research will determine if antibodies generated against these sugars can be used to develop a vaccine that can prevent infection. Published Research Research studies make the greatest impact on the AIDS field and on the broader scientific community when they are published in scientific journals. In the past year, at least 48 scientific publications resulted from amfAR-funded research. Perfecting Tools to Monitor HIV Viral Loads In the March issue of Current Opinion in HIV and AIDS, ARCHE-funded scientist Dr. Sarah Palmer of the University of Sydney, Australia, reviewed the state of knowledge in the detection and monitoring of HIV levels in the blood of infected people. She emphasizes the importance of early ART initiation and the value of monitoring blood HIV RNA levels to ensure the virus is suppressed to below the detection capacity of standard tests. Dr. Palmer goes on to discuss the demand for ultrasensitive virus detection methods and notes that such assays, which can find a single copy of the virus in a milliliter (about a fifth of a teaspoon) of blood, can also be used to document viral "blips," or transient, low-level bursts of virus. She believes these methods will enable researchers to define the source of persistent virus in people on long-term ART, and recently started using the techniques to assess the efficacy of treatment strategies by which latent HIV is chemically coaxed out of a person's infected cells, rendering them vulnerable to attack by ART. Controlling HIV after Stopping Antiretroviral Therapy People with HIV who are successfully treated with ART still have infected cells in which the virus remains silent and invulnerable to attack by the immune system or standard anti-HIV drugs. This is a critical barrier to curing HIV. Several studies show that virus growth quickly returns, in most individuals, within weeks of stopping treatment. In the January issue of the Journal of Infectious Diseases, Dr. Steven Deeks of UCSF, Dr. Una O'Doherty of the University of Pennsylvania, and colleagues described a clinical trial that used a special form of interferon, known as pegylated interferon (PEG-IFN) alpha-2a to suppress the typical rebound in viral growth that occurs after halting ART. They found that 45% of their patients maintained viral loads of less than 400 copies-an amount significantly less than what was expected based on prior treatment interruption studies-when given PEG-IFN in addition to ART before having the ART withdrawn. Four of the subjects had "undetectable" viral loads-less than 48 copies-and stayed off all therapy except the PEG-IFN for a full six months. The authors conclude that they have established "a proof of concept" that HIV growth can be markedly suppressed in people in whom the "detrimental effects of uncontrolled HIV replication on immune function have been partially reversed by ART." Perfecting Gene-Based Therapies Targeting HIV Gene therapy-the use of genetically altered immune cells-is a promising approach to curing HIV/AIDS. However, the cost and potential side effects, which include death, of such an invasive procedure render it inappropriate for most individuals living with HIV. In the April issue of Molecular Therapy, amfAR grantees Dr. Matthew Porteus of Stanford University and Dr. Sara Sawyer of the University of Texas at Austin suggested a safer and potentially more accessible approach-using a person's own genetically modified immune cells. They used an enzyme known as a zinc finger nuclease to insert a cocktail of anti-HIV factors into T cells. The technique mimics the cocktail of anti-HIV drugs used with ART. When all of the factors were present, it provided "virtually complete protection" against infection by the two major strains of HIV-1, R5 and X4. The next step is to perform the same procedure not just in laboratory grown T cells, but in a patient's own immune cells-either T cells or, ultimately, stem cells.
Program Service Accomplishments (3)	Part III, Line 4a-4d (3)	Line 4b: TREAT ASIA: amfAR's TREAT Asia program (Therapeutics Research, Education, and AIDS Training in Asia) involves a network of hospitals, clinics, and research institutions working with civil society to ensure the safe and effective delivery of HIV/AIDS treatments across Asia and the Pacific. The TREAT Asia Network encompasses 23 adult and 20 pediatric sites throughout the region, which collaborate on a variety of projects. TREAT Asia HIV Observational Database (TAHOD) TREAT Asia pioneered the region's first adult observational database for HIV/AIDS, which now includes anonymous data collected from more than 8,526 patients at 23 clinical sites in 12 countries. The information gathered and analyzed through the database informs the development of more effective research and treatment programs, and helps define treatment standards specific to HIV/AIDS in Asia. In 2013, the TAHOD network began recruiting participants for a regional study of hepatitis C co-infection among those living with HIV in four countries: Indonesia, Malaysia, Thailand, and Vietnam. The study began with a screening study to assess how many HIV-positive patients in TREAT Asia participating clinics in these countries need to start treatment for hepatitis C. TREAT Asia will then offer up to 200 of these patients hepatitis C treatment for free. The study aims to develop a pilot model of care for treating hepatitis C in resource-limited settings that can be replicated throughout the region, where treatment for the disease is costly and often inaccessible. TREAT Asia Pediatric Network TREAT Asia's Pediatric Network includes 20 sites in seven countries; these sites share information and best practices in an effort to improve the quality of pediatric care in the region. The TREAT Asia Pediatric HIV Observational Database (TApHOD) was modeled on the adult database, and includes data from approximately 5,030 pediatric patients at 18 clinical sites in Cambodia, India, Indonesia, Malaysia, Thailand, and Vietnam. International AIDS Database TREAT Asia manages the Asia-Pacific section of the International Epidemiologic Databases to Evaluate AIDS (IeDEA), a global collaboration established by the U.S. National Institute of Allergy and Infectious Diseases. Adolescent Research In 2013, TREAT Asia conducted several studies on how HIV affects adolescents physically, socially, and emotionally. TREAT Asia's pediatric sites conducted local studies among their adolescent HIV patients to investigate HIV's impact on their health. Among other issues, they assessed cardiovascular function, bone mineral density, incidence of human papillomavirus, models for reproductive healthcare, and optimizing drug adherence. In addition, TREAT Asia is conducting an ongoing study using an audio-computer-assisted survey instrument (ACASI) to better understand how adolescents experience living with HIV by allowing them to anonymously respond to questions using a computer interface about whether they are taking their medicines; if they have tried alcohol, tobacco, or other drugs; their sexual behavior; and stigma they may have experienced at school or at home. Exploring Links Between HIV and Cancer Among HIV-positive MSM, the risk of anal cancer is twice as high compared to those who are HIV-negative, but little research has been done on this issue in Asia. In 2009, using funding from IeDEA, TREAT Asia began supporting an innovative research study exploring the links between HIV and anal cancer and looking at cancer biomarkers in an attempt to better identify MSM with pre-cancerous anal lesions. Research on HPV and anal cancer risk among MSM is ongoing in the three original sites in Bangkok, Bali, and Jakarta. Building Research Capacity TREAT Asia has implemented a research education program to help network members strengthen their skills in conducting clinical research and to boost the overall quality of care in the region. TREAT Asia organized five workshops and training sessions in 2013, including sessions on managing HIV and hepatitis C co-infection, good clinical practices and research ethics, and clinical management of pediatric HIV. Building Community Treatment Literacy and Promoting Advocacy for Treatment Access Communicating treatment information about a disease as complex as HIV/AIDS can be daunting, but patients' lives depend on it. TREAT Asia works closely with regional organizations to support treatment literacy activities, including the production of "community-friendly" educational brochures on HIV treatment standards in local languages. In 2013, TREAT Asia developed a series of educational materials about hepatitis C infection and treatment titled Life Loves the Liver that includes animated video segments, booklets, and flip charts. All materials have been developed in Bahasa Indonesia, Chinese, English, Malay, Thai, and Vietnamese and will be distributed to TREAT Asia's local, national, regional, and global partners. They will also be made available on TREAT Asia's internal webpage and its public YouTube channel. TREAT Asia also continued to publish lay-language articles about new research in the fields of prevention, treatment, and basic science. The goal of these articles is to explain HIV/AIDS research advances for people living with HIV/AIDS and their families, communities, and caregivers across Asia. The articles appear in the TREAT Asia Report and on TREAT Asia's website, www.treatasia.org. 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention TREAT Asia was well represented at the conference in June 2013 in Kuala Lumpur, Malaysia. In addition to activities during the main conference, TREAT Asia staff and network investigators participated in pre-conference workshops on HIV pediatric and cure research. At the pediatric workshop, a TREAT Asia study was presented on the correlation between HIV drug levels in hair samples and virus control outcomes, and Dr. Annette Sohn, amfAR vice president and director of the TREAT Asia program, participated in a debate on the need for pre-exposure prophylaxis for youths at risk of HIV. At the main conference, TREAT Asia studies were presented on the long-term impact of perinatally acquired HIV infection and antiretroviral therapy in adolescents, the prevalence of hepatitis B and C co-infections among adults in TREAT Asia's regional HIV research network, and the risk of anal cancer among men who have sex with men in Thailand and Indonesia. 16th Bangkok Symposium on HIV Medicine amfAR continued its sponsorship of this annual regional symposium, which was held in January 2013 in Bangkok. Dr. Sohn spoke about human papillomavirus infection among HIV-infected youths. TREAT Asia also supported a special workshop during the symposium on the challenges faced while transitioning perinatally infected children to adult HIV care.
Program Service Accomplishments (4)	Part III, Line 4a-4d (4)	Line 4c: EDUCATION AND INFORMATION: amfAR seeks to translate and disseminate information on important AIDS-related research, treatment, prevention, and policy issues for diverse audiences and to stimulate broad awareness of the need for better treatment and prevention methods. amfAR also publishes a wide range of educational materials, maintains an informative website, and engages respected public figures, HIV/AIDS scientists, and policy makers in communicating the need for continued research on HIV/AIDS. Educational Materials amfAR produces a range of periodicals in both print and electronic formats, including its newsletter Innovations, published twice a year and distributed to more than 40,000 people; the TREAT Asia Report, published and distributed three times a year to more than 5,000 readers in the international health community; and a monthly e-mail newsletter distributed to more than100,000 people. The Foundation's newly redesigned website features news, interviews, and original articles covering science, policy, the global epidemic, and amfAR programs and activities. amfAR also creates and distributes program reports, press releases, and updates on major HIV/AIDS issues, and conducts public service advertising campaigns that have been instrumental in educating policymakers, healthcare professionals, people living with HIV/AIDS, and the general public. The Battle of amfAR amfAR helped promote and organize screenings of The Battle of amfAR, a documentary film telling the story of how Swiss scientist Dr. Mathilde Krim and Hollywood movie star Elizabeth Taylor joined forces to create amfAR in 1985. The film played at prominent film festivals throughout 2013 and was an Official Selection at the Sundance and Tribeca Film Festivals. It premiered on HBO in December 2013. Social Media amfAR vigorously expanded its presence in the social media arena, reaching large numbers of people, including a younger demographic that is often less educated about HIV/AIDS. The Foundation regularly added content to its Facebook page, created an Instagram account, and live tweeted and posted images on Instagram from fundraising and program events. amfAR passed 45,000 likes on Facebook in 2013 and now has nearly 20,000 Twitter followers and nearly 6,000 Instagram followers. Media Outreach amfAR continued to work closely with the media to raise the profile of HIV/AIDS, both domestically and internationally, and to help ensure the accuracy of AIDS press coverage. Articles and reports involving amfAR-many of which included interviews with amfAR spokespeople-were carried in numerous media outlets, including The New York Times, The Wall Street Journal, The Washington Post, the Associated Press, Reuters, Bloomberg News, CNN, and The Huffington Post. amfAR's public awareness efforts are greatly enhanced by the committed support of public figures who lend their voices and donate their time, talents, and resources to help sustain the Foundation's mission. Support of amfAR by prominent public figures began with the late Dame Elizabeth Taylor, and others have followed in her footsteps. amfAR is profoundly grateful for the continuing steadfast support of Global Fundraising Chairman Sharon Stone. In 2013, celebrity supporters included amfAR ambassadors Cheyenne Jackson, Janet Jackson, Milla Jovovich, Liza Minnelli, and Michelle Yeoh, as well as Leonardo DiCaprio, Heidi Klum, Alan Cumming, Aishwarya Rai, Abhishek Bachchan, Ke$ha, Gladys Knight, Jessica Chastain, Dame Shirley Bassey, Hilary Swank, Kylie Minogue, Duran Duran, Rosario Dawson, Rosie Perez, Zachary Quinto, Adrien Brody, Dita Von Teese, Preta Gil, Chelsea Handler, and Carly Rae Jepsen, among many others.
Program Service Accomplishments (5)	Part III, Line 4a-4d (5)	Line 4d: THE GMT INITIATIVE: Since 2007, amfAR has been serving the HIV-related needs of gay men, other men who have sex with men (MSM), and transgender individuals (collectively, GMT) throughout the developing world through its GMT Initiative. Through small, targeted grants to grassroots groups, amfAR helps expand access to HIV education and prevention services; supports advocacy aimed at increasing funding for prevention and treatment services; and works to end the stigma, discrimination, and violence that threaten the lives of GMT and fuel the spread of HIV/AIDS. Community Awards In 2013, amfAR awarded more than $710,000 to 39 groups in Africa, the Caribbean, Eastern Europe and Central Asia, and Latin America for a wide range of projects addressing HIV prevention, outreach, education, advocacy, testing, research, and capacity building. Sample funded projects include: Africa Men Against AIDS Youth Group (MAAYGO) (Kisumu, Kenya) MAAYGO is conducting a needs assessment among GMT community members, health and social service providers, micro-credit institutions, and employers in order to better understand barriers to economic empowerment and improved health outcomes for GMT. The results of the assessment will be used to increase access to health services by helping health and social service providers to create GMT-friendly environments. In addition, MAAYGO will promote economic independence for GMT through job skills trainings and a GMT-focused micro-credit program. Caribbean Kouraj (Port-au-Prince, Haiti) Kouraj will organize a training program to educate key GMT leaders on human rights. These same leaders will also receive training in basic research techniques so they can conduct a series of interviews with GMT to document and better understand the level of human rights abuses and violence GMT experience. The information collected from these interviews will be analyzed and used to develop a human rights brief that will serve as a tool to advocate for greater inclusion of GMT in national discussions on HIV and health, as well as to advocate for reduced stigma and discrimination against GMT. Eastern Europe and Central Asia Safe Pulse of Youth (SPY) (Belgrade, Serbia) SPY is increasing the number of GMT individuals tested for HIV and other sexually transmitted infections through the use of a mobile testing van and at its drop-in center "BGD Checkpoint." SPY will also strengthen linkages to mental health and social support services for GMT living with HIV in Belgrade and document and disseminate cases of stigma and discrimination experienced by GMT in public and private healthcare institutions. Latin America Asociacin Solidaria Para Impulsar el Desarrollo Humano (ASPI-DH) (San Salvador, El Salvador) In its second year as an amfAR grantee, ASPI-DH will expand its "Open Road 2011" project to additional regions in El Salvador and will continue training healthcare providers at 24 public health centers across the country on the needs of GMT people. ASPI-DH will focus on reducing stigma and discrimination within health centers in an effort to encourage uptake of HIV prevention, treatment, and care for GMT. This will be accomplished by organizing "Open Door" days at the centers that have participated in the trainings. ASPI-DH will also deploy patients as undercover evaluators or mystery clients who will visit the centers in order to evaluate the quality of care. "In Action" Awards The GMT Initiative also made three awards as part of its Advocacy in Action program, which supports GMT-led community-based organizations that wish to influence the policies of governments and external donors. Four awards were made under its Evidence in Action program, which documents and evaluates the impact of community-based programs with the ultimate goal of implementing the most workable strategies for stopping the spread of HIV/AIDS. Evidence in Action was developed with support from ViiV Healthcare's Positive Action Program and the Elton John AIDS Foundation. Awards for these two programs in 2013 totaled approximately $150,000. Publications As part of its efforts to raise awareness among governments, donors, and international nongovernmental organizations of the spread of HIV among GMT and to advocate for effective strategies to address it, amfAR publishes a range of reports. In May 2013, amfAR published Achieving an AIDS-Free Generation for Gay Men and Other MSM in Southern Africa with the Johns Hopkins Bloomberg School of Public Health. This report details how underfinancing, discrimination, and stigma undermine efforts to address HIV among GMT in the region and makes recommendations about how policymakers can better address the needs of GMT. Individual country profiles on Botswana, Malawi, Namibia, Swaziland, Zambia, and Zimbabwe were also produced to supplement the report. The GMT Initiative Blog, Grassroots, posted articles throughout the year that discuss various HIV-related issues the GMT Initiative's grantee partners are facing and how these issues impact their lives and organizations. Technical Consultation on Innovative Uses of Communication Technology for HIV Programming for MSM and Transgender Populations amfAR co-hosted this meeting in Washington, D.C., May 2-3, 2013, in partnership with the President's Emergency Plan for AIDS Relief (PEPFAR) and USAID. During the meeting, attending activists from around the world were linked with technical leaders and program planners from the U.S. who are working to combat the HIV epidemic among GMT internationally. Prior to the meeting, amfAR hosted a skills-building session for five GMT Initiative grantees that offered them strategies to increase their programs' effectiveness.
Program Service Accomplishments (6)	Part III, Line 4a-4d (6)	Line 4d: Public Policy: Informed by thorough research and analysis, amfAR is a highly respected advocate of rational and compassionate AIDS-related public policy. The Foundation is engaged in efforts to secure necessary increases in funding for HIV/AIDS research; implement the National HIV/AIDS Strategy; expand access to care and treatment; and protect the civil rights of all people affected by HIV/AIDS. Capitol Hill Briefings Where Are We in Ending the AIDS Epidemic? An Update on the Science, July 18, 2013 amfAR, along with IDSA Center for Global Health Policy and the Elizabeth Glaser Pediatric AIDS Foundation, co-sponsored two briefings that featured leading researchers discussing the latest research on core evidence-based interventions for achieving an AIDS-free generation. Speakers were Dr. Myron Cohen of the University of North Carolina at Chapel Hill, Dr. Laura Guay from the Elizabeth Glaser Pediatric AIDS Foundation, Dr. Renee Ridzon of Akeso Associates, and Dr. Chris Beyrer of the Johns Hopkins Bloomberg School of Public Health. Prescription Opioids, Heroin and Disease Prevention: Law Enforcement, Research, and Community Perspectives, July 23, 2013 The briefing highlighted the need to overturn the ban on federal funding for syringe services programs (SSPs) in the face of an alarming increase in injection drug use in the United States. SSPs are essential for combating the spread of HIV through the sharing of contaminated needles. A short film produced by amfAR, titled The Exchange (see below), was screened and followed by a discussion of program and policy issues critical to advancing public safety and health. Speakers included Seattle Police Chief Jim Pugel, Dr. Jennifer Havens of the University of Kentucky, and Kristin Dubay Horton of the Bridgeport (CT) Health Department. Harm Reduction As one of the earliest supporters of comprehensive harm reduction programs for people who inject drugs (PWID), including syringe exchange, amfAR has played a leading role in advocating the implementation of these lifesaving HIV prevention programs. Addressing the need to overturn the ban on federal funding for syringe services programs, amfAR produced four short films on the wide-ranging public health and economic benefits of SSPs and launched a new website designed to educate policymakers and the public on the urgent need for these programs. Additionally, amfAR's policy office produced a number of issue briefs and fact sheets addressing HIV among PWID and the value of SSPs to this high-risk population, including a map of SSP coverage in the United States. In July, amfAR hosted a two-day think tank on implementation science for PWID. There are highly effective interventions for preventing HIV transmission and acquisition among PWID, but coverage levels remain low, stymied by counterproductive policy and legal frameworks, as well as by a lack of access to individuals in need of services. Some key points of discussion during the event included using implementation science to increase our understanding of how to reach and retain PWID with currently available programs and technology, efforts to distribute low dead space syringes (which have been shown to reduce HIV and hepatitis C transmission among PWID), and addressing mental illness and social issues surrounding drug use (e.g., homelessness). Shaping the Domestic Response to HIV/AIDS amfAR has long advocated the implementation of a comprehensive national HIV/AIDS strategy to address the epidemic in the U.S., where more than one million people are living with the virus. In August, the Public Policy Office contributed an opinion piece to the Huffington Post by amfAR Chairman Kenneth Cole and Rep. Barbara Lee (CA) observing the third anniversary of the National HIV/AIDS Strategy. The editorial summarized progress over the last three years on tackling the AIDS epidemic domestically and called for a renewed commitment by providers, advocates, and policymakers to realize the vision of an AIDS-free generation. Additionally, amfAR produced a number of issue briefs, fact sheets, and infographics showing how cuts to domestic HIV/AIDS programming and research funding through federal sequestration undermine the domestic response to the epidemic. Global Health At the International AIDS Conference in 2012, amfAR released "An Action Agenda to End AIDS," developed with AVAC, to identify major short-term priorities for global AIDS programs together with realistic, annual targets through 2016, in an effort to establish a strong, sustainable foundation for ending AIDS. In 2013, one year after the conference, amfAR produced a follow-up report assessing the world's progress to date. The report describes progress being made in certain key areas, including increases in the total number of people on ART, the amount of pregnant women living with HIV who received antiretroviral medication, the number of men circumcised, and the estimated number of people eligible for ART under new therapy guidelines. The report also identifies areas where the global AIDS response is falling short, including persistent coverage gaps in scaling up core interventions, widespread stigma and discrimination, and inadequate access to key diagnostic tools. Additionally, in 2013, amfAR reported extensively on the impact of budget sequestration on global health, with specific attention to how funding cuts to the President's Emergency Plan for AIDS Relief (PEPFAR)-would undermine the decade's worth of progress made by the largest international response program to the global AIDS epidemic. GMT Gay men, other men who have sex with men, and transgender individuals-collectively referred to as GMT-remain one of the hardest hit and most underserved populations in the global HIV/AIDS epidemic. amfAR's policy office works closely with the Foundation's GMT Initiative to advocate for expanded access to HIV prevention and treatment services for GMT worldwide, and to fight the stigma and discrimination that make GMT more vulnerable to HIV infection and inhibit equal access to care. In May, amfAR released a new report-Achieving an AIDS-Free Generation for Gay Men and Other MSM in Southern Africa-on funding and policy related to tackling the HIV epidemic among gay men and other MSM in Southern Africa (see GMT Initiative). An issue brief released by amfAR in August, titled Tackling HIV/AIDS Among Key Populations: Essential to Achieving an AIDS-Free Generation, argues that ending the AIDS pandemic will not be possible without greatly increased efforts to reduce new infections and prevent AIDS-related deaths among key populations at highest risk of HIV. The brief reports that key populations (including GMT) are severely and disproportionately affected by HIV on a global level-with epidemics among these individuals continuing to grow despite an overall decline in new infection rates-and that they are largely neglected by HIV treatment and prevention efforts as a result (directly and indirectly) of discriminatory laws and policies. The issue brief highlights a few of the evidence-based strategies that are available to substantially reduce the number of new infections and AIDS-related deaths among key populations.
Policies	Form 990, Part VI, Section B	Line 11 - The Form 990 was prepared by a nationally renowned accounting firm in conjunction with the organization's financial department. A copy of the draft Form 990 was circulated to the full Board of Trustees for discussion and comment. Each Board Member was provided ample opportunity to comment on the information contained in the 990 prior to its filing with the Internal Revenue Service. Line 12 - Each officer, director, trustee and key employee of amFar ("foundation") is required to annually disclose any conflicts of interest that arise by virtue of employment, board service, or position with the foundation. The foundation monitors compliance with its conflict of interest policy through an annual questionnaire/disclosure statement that is distributed to these individuals. Potential conflicts are investigated immediately. LINE 15 -AMFAR ("FOUNDATION FOR AIDS RESEARCH") UNDERTAKES A THOROUGH PROCESS TO ENSURE THAT THE COMPENSATION IT PAYS TO ITS TOP MANAGEMENT OFFICIAL AND ALL OF ITS OFFICERS AND KEY EMPLOYEES IS REASONABLE GIVEN THE MARKET IN WHICH THE FOUNDATION OPERATES. AN INDEPENDENT CONSULTING FIRM QUALIFIED IN THE AREA OF NONPROFIT COMPENSATION PREPARES AN ANALYSIS OF MARKET COMPENSATION RANGES BY JOB FUNCTION AND PRESENTS IT TO THE COMPENSATION COMMITTEE OF THE BOARD. ON THE BASIS OF THIS INFORMATION, STAFF COMPENSATION IS DETERMINED ACCORDING TO SALARY RANGES APPROVED BY THE COMPENSATION COMMITTEE OF THE BOARD, IN CONSULTATION WITH THE CEO AND CFO. CEO COMPENSATION IS REVIEWED AND DETERMINED BY THE COMPENSATION COMMITTEE OF THE BOARD UTILIZING THE INDEPENDENT CONSULTANT ANALYSIS.
Disclosure	Form 990, Part VI, Section C	LIne 19 - amfar makes its Form 990 available to the public by retaining a copy at its place of business and on its website, www.amfar.org. The Form 990 is likewise published on the internet at www.guidestar.org. The Foundation's financial statements are made available in its annual report and on its website. The Foundation's governing documents and conflict of interest policy are not ordinarily made available to the public, but, if requested, will be provided at management's discretion.
Functional Expenses	Part IX, Lines 1 & 3	The Foundation for AIDS Research reports its grants net of grant returns or recoveries. Periodically, grants remitted to charitable organizations are returned to AMFAR for a variety of reason. On Schedules F & I, grants are reported irrespective of whether they were ultimately returned to AMFAR since categorizing the "returned" amounts would be time consuming. Therefore, amounts reported on Part IX, Line 1 will not tie to total grants on Schedule I; amounts reported on Part IX, Line 3 will not tie to total grants on Schedule F.
Other Changes in Net Assets	FORM 990, SECTION XI, LINE 9	CHANGE IN VALUE OF THIRD PARTY TRUST................ ($29,887) ---------- TOTAL LINE 9 ($29,887) ==========